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Abstract 
GARY A. THIWDEAU 
Under the supervision of Professor R. N. Swanson 
Sodium D-thyroxine was evaluated for possible embryotoxic and/or 
teratogenic effects following oral administration in New Zealand White 
·rabbits. All animals utilized were alert9 active and apparently 
disease-free virgin does weighing three and one-half to four kilograms. 
Rabbits were individually housed in stainless steel batteries and 
maintained on a commercially available palletized diet and mineral 
supplement. Feed and water were provided� libitum in animal quarters 
air conditioned to minimize environmental temperature fluctuations. 
Following a 14-day post-delivery observation period does were bred 
to New Zealand White bucks and randomly allocated to one of two experi­
mental groups or the control group each containing 10 animals. 
A pure sodium salt sample of the dextro isomer of thyroxine 
(NaD-T4) was supplied for experimental use as a fine, cream-colored 
powder. The hormone was dissolved in an alkaline, hot ethanol media 
to produce solutions suitable for oral administration. 
Control animals received 0.5 ml. of diluent each day of pregnancy. 
Animals in Experimental Group I received 2.0 mg.· of NaD-T4 in 0.5 ml. 
of dilµent each day of pregnancy. '3-· Does in Experimental Group II 
received 0.5 ml. of diluent during the first 15 days of gestation and 
2.0 mg. of NaD-T4 in 0.5 ml. diluent daily the last 15 days of pregnancy. 
Unanesthetized pre�nant does were sacrificed on day 29 of their 
gestation periods by massive air embolism induced by cardiac puncture. 
Data were obtained from 59 control, 6J Experimental I, and 56 Experi­
mental II fetuses following post-mortem cesarean delivery. Increased 
doe lethality did not occur in experimental animal groups at the 2.0 mg. 
p.o. daily dosage level employed. Macroscopic uterine pathology was 
not observed in either control or experimental does. 
Intrauterine mortality rates were similar in control and Experi­
mental II animal groups. An increase of over 20% in intrauterine 
mortality was noted in Experimental I group do�s. _Observed discrepan­
cies in embryotoxicity, at the same daily p.o. dosage level, are 
attributed to chronic fetal exposure during a more susceptible develop­
mental stage. In every case, non-viable Experimental I and II fetuses 
were undergoing sterile intrauterine autolysis of approximately 24-48 
hour durat�on when delivered on day 29.· 
All rabbit fetuses were critically examined for embryotoxic and/or 
teratogenic effects following cesarean delivery. Fetuses were examined 
externally, internally, and roentgenologically for over 100 primary 
pantasomatous and merosomatous terata. Exhaustive examination of 
every fetus obtained in the study failed to uncover a single anomaly. 
�rgan weight data including wet/dry heart, wet liver and wet right 
kidney and lung weights were obtained from fetuses judged viable fol­
lowing·cesarean delivery. Results of statistical analysis indicated 
highly �ignificant treatment effects (fetal organ weight increases) in 
both Experimental I and II animal groups. Absolute increases were 
greater in Experimental I doe fetuses who were exposed to the drug 
daily. 
No histopathology was observed in placental tissue or maternal 
heart sections obtained from each control and experimental doe. All 
fetal liver, kidney and lung tissue sections were judged nonnal. 
Increased liver, kidney and lung weights observed in fetuses obtained 
from does medicated with sodium dextrothyroxine were not associated 
with microscopic alterations or histopathology. 
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Cardiovascular diseases are by far the leading cause of death 
in the Western World. The present epidemic of atherosclerosis is 
considered by many as the major health challenge of our Western 
culture. 
Etiology of atherosclerosis is unquestionably multidimensional. 
Although it is difficult to establish relative importance of various 
"risk" factors, there is a wealth of pathological and epidemiological 
data, from both animal and clinical research endeavors, that point to 
a direct causal relationship between elevated seru.� cholesterol 
levels, concomitant atherosclerosis, and degenerative cardiovascular 
disease. 
Warranted implication of hypercholesterolemia as a causal factor 
in atherogenesis has stimulated an intensive and continued search for 
safe and efficacious hypocholesterolemic agents. 
Blood lipids circulate as four basic classes of compounds: 
alpha-lipoproteins, beta-lipoproteins, triglycerides and free fatty 
acids. Lipoproteins serve as vehicles for transport of hydrophobic 
blood lipids. Therefore, reduction in serum lipoprotein levels would 
result in concomitant lowering of total serum lipids. Ignorance of 
biochemical control mechanisms involved in regulation of total serum 
lipoprotein levels has resulted in attempts to regulate individual 
blood lipid moieties employing chemotherapeutic or dietary approaches. 
2 
Chemotherapeutic approaches have. pr?ve� more consistently reli­
able than dietary control in hypercholesterole�ic treatment programs 
now in progress. Presently available hypocholesterolemic drugs act as 
inhibitors of cholesterol synthesis or accelerate its degradation and/ 
or excretion. 
Many authorities believe that prophylactic treatment of idio­
pathic hypercholesterolemia will prevent atherosclerotic plaque 
formation which almost inevitably precedes clinical arteriosclerosis 
and subsequent degenerative heart disease. Under National Heart 
Institute auspices, a multiclinic double-blind. study is now in progress 
to evaluate long term hypocholesterolemic effectiveness of clofibrate,* 
nicotinic acid,** and dextrothyroxine.*** In approximately two years, 
final analysis of data obtained from these studies should determine 
if long term administration of hypocholesterolemic drugs actually 
reduces morbidity and mortality in coronary heart disease. 
Of the three hypolipemic drugs under study, dextrothyroxine 
appears particularly promising. L:>wering serum lipids in hyperlipemic 
individuals is r pid, predictable and relatively free from side effects 
attributable to calorigenesis or catecholamine synergism._ 
• ATROMID-S, Ayerst laboratories, .Rouses Point, New York, N. Y. 
** NICANGIN, Draco AB, IJJ.nd, Sweden 
***CHOIDXIN, Flint Laboratories, Morton Grove, Ill. 
In spite of a veritable avalanch� of published papers concerning 
results or laboratory studies and clinical trials there is a con­
spicuous absence of teratologj" studies employing dextrothyroxine. 
Isolated liter�ture reports related to liver and heart weight 
alterations following dextrothyroxine administration and lack or 
teratologic data prompted these investigations. 
REVIEW OF LITERATURE 
Rationale f.E£_ Hypolipemic Therapy 
Cardiovascular diseases are clinical entities of multifaceted 
etiology. There is a wealth of pathologic, epidemiologic, clinical 
and investigative data, however, that point to a direct causal 
relationship between elevated serum lipids, atherosclerosis, and 
degenerative heart disease.1' 2, 3, 4• 5 Indeed, the conditio 
� qua n£U for atherogenesis in pri:nates is hypercholesterolemia.6 
Elevated serum triglycerides have also been implicated in athero-
genesis but with less corroborating documentati�n.7' 8 Critical 
appraisal of available data suggests, therefore, as an epidemiologic 
preventive measure or therapeutic goal in heart disease, effective 
control of hyperlipemia, particularly hypercholesterolemia. 
4 
Hypercholesterolemia, subsequent atherosclerosis and related 
cardiovascular alterations are seldom noted in animals dying of 
wasting disease9 or starvation.10 Similarly, data from several 
studies have indicated. significant decreases in coronary heart 
disease mortality and/or morbidity in animal populations whose serum 
cholesterol levels were maintained within normal ranges by rigid 
dietary regulation.11, 12• lJ Despite these facts, successful 
alteration of dietary habits of large populations, derived from myriad 
national and ethnic groups, has been found impossible due to multiple 
problems of comprehension and/or compliance. As sole therapy, chemo- • 
therapeutic approaches have proved more consistently reliable than 
dietary regulation in hypercholesterolemic treatment programs now in 
5 
progress. Presently available hypocholesterolemic drugs act as 
inhibitors of cholesterol synthesis or accelerate its degradation and/ 
or excretion. 
Many experimental drugs have been found highly effective hypo­
lipemic agents but have not been released because of real or potential 
dangers. Several hypolipemic drugs now marketed in the United States 
under Food and Drug Administration approval have exhibited only 
limited effectiveness or have not found patient acceptance because of 
annoying if not dangerous side effects. Only those chemotherapeutic 
agents of practical and/or theoretical importance as hypolipemic 
agents have been discussed. 
Pyridyl Carbine s� Pyridinesulfonic (Pyridinealkanesulfonic) Acids 
In an extensive and systematic study of compounds showing tran­
quilizing effects Wright tl &.14 found the pyridyl carbinol a,a­
diphenyl-B-(4-pyridyl) ethanol had marked hypocholesteremic activity 
in mice. Observed hypolipemic efficacy stimulated interest in prepa­
ration and testing of related compounds. 
Table 1 shows 11 pyridyl carbinols which were found effective in 
lowering serum cholesterol in treated mice by 20% or more. This 
group of compounds, although effective hypolipemic agents, were found 
toxic and abandoned. 
Interest in aminosulfonic acids, as cholesterol lowering agents, 
by Freifelder and Wright15 prompted hydrogenation and testing of 
several pyridine and pyridinealkanesulfonic acids including 2-(2-
Pyridine) ethanesulfonic acid and 3-Pyridinehydroxyroethanesulfon·c 
acid. Lack of physiological activity or delayed toxicity, including 
intermittent convulsions and death in mice, discouraged further 
testing among this group. 
TABLE 1--Effectiveness of Related Pyridyl Carbinols in Reduction 
of Serum Cholesterol in Mice 
Calculated 
6 
dose, Serum Cholesterol 
Compound* ( mg./kg./day) (% reduction) 
4 100 Z? 
5 100 36 
500 48 
8 250 31 
10 500 65 
100 30 
15 312 34 
17 219 57 
18 100 46 
20 4oo 36 
22 100 49 
*Compounds synthesized by Wright et al. and reported in J. Med. Chem. 
z., 115 (1964) . - -
Substituted Pipe azines 
Schmidt and Martin16 found both chlorocyclizine** and N-(B­
phenyl-B-3-chlorophenyl-B-hydrox:yethyl)-N'-methylpiperazine effective 
as hypocholesterexnic agents in mice. H�wever, hepatic hyperplasia 
occurred in treated animals receiving therapeutic (hypocholesteremic) 
dosage levels. 
**DIPARALENE, Abbott Laboratories, North Chicago, Illinois 
7 
Wright and Martin17 prepared 24 related ( substituted) piperazines 
hoping to find an effective hypolipemic congener devoid of hepatic 
hyperplasia noted in both parent compounds. Congeners tested showed 
varying degrees of hypocholesteremic activity but were invariably 
accompanied by hepatic hyperplasia. Table 2 shows both hypocholester­
emic efficacy and % increase in liver weight following administration 
of 10 substituted piperazines in mice. 
Basic Carbinols � Related Compounds 
Triparanol,* a derivative of 1, 1, 2-triphenylethanol, was syn­
thesized by Palopoli il !J:.. 18 in 1958 and first reported as a specific 
inhibitor of cholesterol biosynthesis in rats by Blohni and coworkers 
""' 10�0 19, 20 
-· -✓✓✓ • It was soon reported effective :u:, reducing cholesterol 
concentrations in plasma, liver, and other experimental animal 
tissues21• 22• 23, 24 and in human serum.25• 26• Z?, 28 However, it 
soon became apparent that as cholesterol levels decreased, plasma and 
tissue concentrations of its biogenetic precurser, desmosterol, 
increased. 22• 23 Blohm� il.19 concluded that triparanol inhibited 
cholesterol biosynthesis after formation of the basic sterol nucleus. 
Avignan et al. 29 established A 24 reductase blockade as the exact --
site of inhibition. Increases in desmosterol levels produced total 
plasma sterol concentrations higher than concomitant determinations of 
cholesterol had indicated and were responsible for observed side effects. 
*MER-29, Wm. s. Merrell Company, Cincinnati, Ohio. 
TABLE 2--Effectiveness of Substituted Piperazines in Reduction 
of Serum Cholesterol in Mice and Associated Hepatic 
Hyperplasia 
Calculated 
dose, Serum Cholesterol Liver Wt. 
Compound* (mg. /1f.g. /day) (% reduction) (% increase) 
1 400.0 31 8 
2 87.5 17 24 
3 43.8 13 30 
375.0 55 16 
7 500.0 59 24 
15 175.0 8 25 
16 200.0 33 46 
17 62. 5 53 
18 62.5 27 . 28 
500.0 8 33 
8 
*Compounds synthesized by Wright tlil· and reported in J. Med. Chem. !!.: 391 (1968) • 
Although depression of serum cholesterol levels followed tri­
paranol administration lack of potency was a distinct initial dis­
advantage.30 Toxic manifestations of treatment in animals, including 
man, involved ectodermal lesions including ichthyosis, lenticular 
opacities and alopecia. Wexler31 has reported triparanol-treated 
rats showed marked interference with normal reprpductive activity 
including prolonged gestation periods, increased number of stillborn, 
and resorption of fetuses. 
Short £i il.·32 synthesized 58 basic carbinols, primarily by 
Grignard reactions, in an unsuccessful search for compounds similar to 
triparanol but effective at lower dosage leveis for reduction of total 
serum sterols. Administration of basic carbinols, as a group, resulted 
in accumulation of desmosterol in tissue, including aorta. There is 
9 
no direct evidence from animal experimentation to prove or disprove 
· 
34 atherogenicity of desmosterol . However , Horlick33 and Clark tl 21· 
have pointed out that lowering serum cholesterol levels by drugs 
which result in accumulation of precursor substances of unknown 
atherogenic potential may not be followed by atherosclerotic 
amelioration or inhibition . 
Trifluperidol � Related Butyrophenone Compounds 
Hypocholesterolemic activity was first attributed to tri­
fluperidol* (TFP) and WY-3457 , two antipsychotic-butyrophenone com­
pounds , by Simpson and Cooper .35 • 36 Subsequent . data published by 
Clark tl !!.34 extended and corroborated these findings . In addition , 
they noted accwu�lation of 7-<;iehydrocholestsrol , a cholesterol pre-
cursor , in serum of TFP treated animals and correctly attributed 
hypocholesterolemic activity to blockade of A7 reductase . 
AY-9944, ** another inhibitor of A 7 reductase in an:unals , has 
exhibited promising hypocholesterolemic properties and proved useful 
in studies of cholesterol biosynthesis in man.37 
Observations by Simpson tl �.36 showing administration of 
WY-3457 produced toxic effects similar to triparanol , suggested that 
TFP or AY-9944, simil�r butyrophenones , would produce related toxic 
manifestations 1n· treated animals . However,  attempts to produce toxic 
skin and lens changes ,  attributable to TFP or AY-9944 administration , 
*TRIPERIDOL , McNeil Laboratories , Inc . ,  Fort Washington , Pa . 
**Trans-1 4-vis-( 2 chlorobenzylaminomethyl) cyclohexane dihydro-
chloride , Ayerst Laboratories , New York , N .  Y .  
... : 
10 
have failed . Instead of desmosterol accumulation in tissues , admin­
istration of ·these compounds results in extrapyramidal tract symptoms 
and sedation related to elevated serum 7-dehydrocholesterol levels .34 
Nicotinic � 
Nicotinic acid was first reported effective in reduction of 
elevated serum cholesterol levels in man and rabbits by Altschul tl !,l. , 
in 1955 .38 Verification of hypocholesterolemic activity has been 
amply documented in serum of several animal species including 
man .39 , 40, 41 , 42 
Definite hypocholesterolemic mechanisms exerted by nicotinic 
acid have not been established. Schade tl tl,.43 have reported decreases 
in both total liver cholesterol and hepatic sterol biosynthesis in 
nicotinic acid treated rabbits. Mechanism of action was a presumed 
competition of nicotinic acid for acetyl coen zyme A required for both 
conj ugation of administered drug and cholesterol biosynthesis from 
acetate. In 1958 Altschul et al.44 reported increased basal metabolic - -
rate (BMR) in nicotinic acid treated patients and suggested hypo­
cholesterolemic activity was secondary to thyroid stimulation. How­
ever, Duncan and Best45 could find no differences in mean oxygen 
consumption between nicotinic acid treated _rats and control animals . 
Furthermore, no evidence of hyperthyroidism or elevations in metabolic 
rates have been reported in long-term studies of nicotinic acid admin­
istration.46 •  47 
Severe cutaneous flushing and burning sensations caused by nico­
tinic acid administration were considered by Kritchevsky 21 il.48 
11 
as manifestations of "stress" and suggested a· 11stress mechanism" to 
explain observed hypocholesterolemic effects following treatment. 
This hypothesis is no longer considered tenable . Most reactions 
subside rapidly whereas hypolipemic effects can be maintained by con­
tinued medication .49 Furthermore, adverse reactions can often be 
avoided altogether by manipulation of dosage schedules .SO 
Reports by Achor il il.46 and Parsons tl tl.47 indicate that 
anorexia and weight loss do not account for hypoliperaic effects of 
nicotinic acid administration in roan .  
Pentaerythritoltetranicotinate , trial name 8 AL (Perycit*) ,  is an 
ester of nicotinic acid reported by Sigroth51 to be as  effective as 
nicotinic acid in hypocholesterolemic activity while showing less 
marked side effects . 
Perycit has passed toxicity tests performed on rats and dogs . 
Oral LDso in mice exceeds 10 , 000 mg . /kg. and tests for possible 
teratogenic effects in rats and rabbits proved negative at thera­
peutic dosages ( 3  Gm./day) . Long term follow up of human patients 
receiving 3 Gm ./day of Perycit for hypercholesterolemia have shown it 
effective and relatively free of most trou�lesome side effects ( flush, 
gastritis and liver damage) associated with long tenn nicotinic acid 
administration . Liver function tests including bilirubin , thymol 
turbidity, alkaline phosphatase ,  and SGOT remained within normal 
ranges in patients who bad received 8 AL,  3 Gm . /day , for six years . 
*PERYCIT brand of pentaerythritoltetranicotinate, AB Bofors, Nobel­
Pharma, Sweden . 
As with nicotinic acid, observed hypocholesterolemic activity was 
dose dependent and reversible.51 
Probucol {DH-581) 
Probucol (DH-581) is a lipophilic bis-phenol (4,4 ' -isopro­
pylidenedithio-bis-2 , 6-di-t-butylphenol) described by Barnhart 
12 
� tl.52 as a new and potentially useful hypolipidemic agent in several 
species. Admi.."listration of 200 mg . /kg. /day of probucol resulted in 
highly significant reduction of serum cholesterol levels in mice , 
rats and primates ( cynomolgus monkeys ). No significant changes in 
liver weight , liver cholesterol, or liver triglyceride levels were 
noted. 52 
Minimal oral absorption of probucol, an effect previously 
associated with structurally related compounds, 53 may account for low 
incidence of serious side effects reported in initial clinical trials . 54 
Inhibition of lipoprotein formation or transport has been suggested as 
a mechanism of action . Acetate incorporation studies have indicated 
probucol has no effect on late stages of cholesterol biosynthesis. 5 2 ,  
55, 56 
Neomycin 
Samuel and Steiner57 first reported hypocholesterolemic activity 
following oral administration of neomycin. Hypolipemic effects were 
reported dependent on oral administration after parenteral use studies 
failed to reduce serum cholesterol levels in laboratory animals or 
man.58 Since neomycin exhibited poor gastrointestinal absorption its 
hypolipemic effect was ascribed to digestive tract activity . Cayen59 
has reviewed studies performed in attempts to elucidate possible 
hypolipemic mechanisms . 
Steatorrhea induced malabsorption syndromes , following dramatic 
fecal fat excretion , was first suggested as a possible hypolipemic 
mechanism60 but is no longer considered tenable . 61 • 6 2 • 63 
Powell tl !!.63 have proposed post-treatment alterations of 
intestinal microflora as a possible mechanism of action . However , 
recent data have cast doubt on the true importance of microflora 
changes in explaining hypolipemic effects of neomycin . 64 , 65 , 66 
Cayen59 suggests hypocholesterolemic effects �f neomycin result 
13 
from selective bile acid precipitation . His data extend and strengthen 
conclusions of Van den Bosch et a1 .67 and earlier workers64 • 65 that - -
hypolipemic effects are due not to antimicrobial activity but to 
numbers of available polybasic radicals in the molecule . 
Estrogen � Comnounds { SQ 8,576 ) 
Estrogens are naturally occurring compounds known to block 
cholesterol biosynthesis .68 , 69 Mukherj ee and Bhose70 reported 
blockade of cholesterol biosynthesis by estradiol-17 beta at pre­
mevalonat� steps and suggested its possible usefulnes s  as a hypo­
cholesterolemic agent . Estrogenic compounds exhibit multiple biological 
activities . However , structural alteration of these compounds has 
resulted in discovery of pharmacologic agents possessing only selective 
estrogenic activity .71 
2 5 6 6 9 2  �SOUTH DAKOTA STATE UN IVERS ITY L IBRARY 
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Lerner il il · 7 2 reported the compound 2, 2 u 1 -( l-methyl-4, 4-di­
phenylbu tylidine) bis ( p-phenyleneoxy) bis-triethylamine ( SQ 18 , 576 )  its 
oxalate salt (SQ 10,591) and its citrate salt ( SQ 11 ,071) effective in 
blockade of cholesterol synthesis between mevalonate and lanosterol in 
rats. SQ 10, 591 was also reported effective in reducing free fatty 
acids and triglycerides. 
SQ 18 , 576 and its related compounds represent the newest group of 
promising hypolipemic agents now under study. 
Cholestyramine Resin 
Cholestyramine* is a nonabsorbable chloride salt polymer of a 
basic anion exchange resin reported to contain quaternary ammonium 
groups attached to a styrene-divinyl benzene skeleton.73 
Orally administered cholestyramine has been reported to sequester, 
!!!_ m2., both unconjugated and conjugated bile acids thus increasing 
fecal bile acid output . 59 Inability of cholestyramine to lower 
blood sterols in rats and swine has been attributed to compensation 
for increased fecal loss of bile acids by corresponding increases in 
both hepatic74, 75  and intestina1?6 , 77 cholesterol biosynt.�esis . 
Dramatic reduction of elevated serum cholesterol levels and bile acid 
have been . reported following oral administration in hypercholestero­
lemic humans.78 • 79 , 80 Attempts to compensate for increased bile 
acid excretion also occur in humans . However , compensatory increases 
in rate of sterol synthesis appear limited.73 
*QUESTRAN, Mead Johnson Laboratories Div. of Mead Johnson & Company, 
Evansville, Ind . 
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Fallon and Woods81 have demonstrated acceptability of long-term 
cholestyramine therapy ·in well motivated hypercholesterolemic patients. 
Results of clinical studies have shown cholestyramine, in general, to 
be well tolerated.82 Steatorrhea is seldom reported if recommended 
dosage levels of 12 to 15 Gm. daily have not been exceeded. �ld 
gastrointestinal distress and perianal irritation trouble some 
patients. Allergic manifestations attributable to cholestyramine have 
been rare. 
Thyroxine Analogues 
The chemistry and physiology of the parent thyroid hormones 
J : 5 :J ' :5 ' -tetraiodo-L-thyronine (LT4) and J :5 : 3 '-triiodo-L-thyronine 
well known that administration of thyroxine or thyroxine analogues 
results in multiple biologic activities including both increased basal 
metabolic rate ( BMR) and reduction of serum cholesterol levels. Effects 
on biosynthesis, distribution, absorption and catabolism of cholesterol 
have been studied extensively in both experimental animals84, 85, 86 , 87 
and in man.88, 89, 90 
Administration of thyroxine and thyroxine analogues results in 
increased degradation. and excretion of cholesterol. However, except in 
hypothyroid animals utilization of natural thyroxine as an effective 
hypocholesterolemic agent has not been feasible because of pronounced 
calorigenic activity including increased myocardial oxygen consumption 
rates. 91 
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Cutting tl tl.92 first suggested that effective hypocholestero­
lemic activity of certain thyroid analogues could be divorced from 
increased metabolic rate (BMR) in man. Stamler tl �.93 reported 
similar observations in chicks . However , clinical studies have shown 
hypocholesterolemic effects of most thyroid dervatives and isomers 
(Table 3) cannot be dissociated from undesirable idiosyncrasies and 
metabolic side effects.94 • 95, 96 , 97 ,  98 
TABLE 3--List of Thyroxine Analogues Tested For Hypocholesterolemic 
Activity in Man 
Chemical 
name 
3 : 5 : 3 ' : 5 ' -tetraiodo-L-thyronine 
3 : 5 : 3 1 : 5 ' -tetraiodo-D-thyronine 
3 : 5 : 3 ' : 5 ' -tetraiodothyroacetic acid 
3 : 5 : 3 ' : 5 ' -tetraiodothyroformic acid 
3 : 5 : 3 ' -tri " odo-L-thyrcni.ne 
3 : 5 : J ' �triiodo-D-thyronine 
3 : 5 : 3 ' -triiodothyroacetic acid 
3 : 5: 3 ' -triiodothyroformic acid 
3 : 5-diiodo-L-thyronine 
3 : 5-diiodo-D-thyronine 
3 : 5-diiodothyroacetic acid 
















Thorp and Waring99 first reported parachloropheno.xyisobutyric 
acid (clofibrate, CPIB *)  and its ethyl ester to be effective hypolipemic 
agents in rats. Hypolipidemic activity was subsequently established in 
*ATROMID-S, Ayerst Laboratories, Rouses Point, New York, N. Y .  
man by Oliver100 in England and by Hellman tl &.101- and others10 2 • 
103, 104 . 
in the United States. 
Precise hypolipidemic mechanisms of clofibrate are unknown. 
Azarnoff tl &.105 have suggested pre-mevalonic acid blockade of 
cholesterol biosynthesis as a possible hypolipemic mechanism. CPIB 
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has been found more effective in lowering serum triglycerides than 
serum cholesterol and is currently considered by some the drug of 
choice in treating types III, IV, and V hyperlipoproteinemias .
106, lO?, 
108 
Clofibrate is well tolerated by most hyperlipemic individuals 
although cardiac arrhythmias , 109 reduction in fibri�ogen levels110 
and potentiation of administered anticoagulants111 have been reported 
following oral administration in man. 
Sodium D yroxine* 
Utilization of natural thyroxine in euthyroid subjects for 
reduction of elevated cholesterol levels has proved unsuitable , in 
most cases , because of pronounced calorigenic activity. 112 • ll3 , n4 
Evidence proving molecular alteration of steroid hormones could 
produce accentuation or diminution of specific biologic activity led 
Best and Duncan115 to suggest that modification of the thyroxine 
molecule might result in accentuation of hypocholesterolemic effects 
relative to calorigenic activity. Lerman and Pit tc-Ri vers116 first 
reported triiodothyroacetic acid (TRIAC ) effective in lowering elevated 
*cHOLOXIN , Flint Laboratories , Morton Grove , Illinois. 
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cholesterol levels without concomitant elevation of the ba.sal metabolic 
ra to . Dextro-isomers o·f thyroxine were subsequently shown to be 
particularly promising as cholesteropenic agents exhibiting only mild 
myocardial calorigenesis and weak catecholamine synergism. 117, 118 , 
119, 120, 121 
Initial favorable clinical and experimental data on the sodium 
salt of the dextrorotatory isomer of thyroxine, D-J:5: 3 ':5 '-tetra­
iodothyronine, has been reviewed and summarized by Starr. 122, 123, 
124, 125 
Difficulty obtaining pure samples of D-thyroxine limited research 
investigations of any magnitude until Ginger126 developed a process 
racemic hormone. 
Mechanism of Action : NaD-T4 
The mechanism of action of the parent thyroid honnones has been 
reviewed in depth by Chiu, 127 Olson and Vester,128 and Steinberg.129 
Dextrothyroxine's  mechanism of action has also been extensively 
reviewed.lJO, 131, 132 Available evidence indicates that D-thyroxine 
stimula�es hepatic oxidative catabolism, resulting in increased biliary 
route and fecal excretion of cholesterol and its degradation products. 
The mechanism constitutes a stimulus to a normal excretory pathway and 
is considered physiologic.  D-thyroxine does not inhibit cholesterol 
synthesis and abnormal metabolic intennediates do not accumulate in 
the blood. 
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This physiologic mode of action has been demonstrated experi­
mentally by Hoobler tl !_!. 133 who found that control rats administered 
cholesterol-4-c14 excreted more than 90 per cent of the injected 
radioactive material in eleven and one-half days; rats receiving 
therapeutic doses of NaD-T4 excreted a similar amount in seven days. 
Rabinowitz et !_l. 134 have reported sodium dextrothyroxine markedly 
effective in accelerating degradation of cholesterol in man. 
Absorption, Tissue localization, and Excretion : NaD-T4 
Measurements of butyl-extractable iodine (BE!) concentrations and 
protein-bound iodine (PBI) in serum of animals treated ith orally 
administered sodium dextrothyroxine indicate direct absorption into 
the bloodstream from the gastrointestinal tract and preferential 
binding to serum proteins. 119,  135 Bravermanl36 noted that PBI lsvels 
alone were deceptive in establishing normal ranges because of depen­
dence upon particular thyroid hormone employed. :attyl alcohol extrac­
tion is known to be specific for thyroxine and chance contaminants are 
less likely to introduce error in this procedure when compared with 
PBI methods. BEI techniques also offer technical advanta ges when 
compared to older distillation procedures. 
Little is known concerning the fate of sodium dextrothyroxine once 
it has entered the bloodstream of a pregnant animal. It has been known 
for years, however, that mammalian placentas are permeable to naturally 
occurring thyroid hormones.137 Regardless of mechanisms involved ,  it 
can be concluded from interpretation of available data that significant 
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quantities of both T3 and T4 cross the placenta in mammals.
138 ,  139 , 
140, 141 Benson tl_ ai.·142 have shown that �thyroid infants can develop 
normally if there are adequate levels of circulating maternal thyroxine 
and a functional placenta. It has been suggested that D-thyroxine in 
doses of 1. 0 to 2 . 0 _ mg. daily may be substituted for L-thyroxine in 
maternal thyroid deficiencies, but possible fetal alterations and/or 
idiosyncrasies related to use of the synthetic isomer must be con­
sidered.143 
A classic paper related to excretion and physiological disposition 
of D- and L-thyroxine in rats was published by Tapley et al., 144 in 
1959. pifferences in distribution and half-life of .radioactive 1lJl_ 
tagged I- and D-thyroxine suggested , for the first time , a plausible 
mechanism of action explaining differences in metabolic activity pro­
moted by the two isomers in peripheral tissues • 
. To vivo investigations completed prior to the published work of 
Tapley tl ai. 144 demonstrated that D-thyroxine reduced serum cho­
lesterol levels in hypercholesterolemic euthyroid animals. Eht in 
contradistinction to the L isomer, such reductions occurred in the 
relative absence of characteristic metabolic effects elicited by 
administration of natural thyroid hormones. Depending on the bio­
assay employed D-thyroxine has been reported to be one-tenth as active 
as the L isomer.145, 146, 14? 
Results of in vitro biochemical studies published by Kritchevsky 
tl !];. 148 seemed to contradict previously reported clinical observa­
tions in that both the D and L isomers of thyroxine proved equally 
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effective promoting morphologic changes in mitochondria and "uncoupling" 
oxidative phosphorylation reactions. Tapley et ai. 144 attempted to 
explain the observed !n, !!!Q. and 1n. vitro differences between the two 
isomers. Using 1131 labeled L- and D-thyroxine they proved that L­
thyroxine was much more widely distributed, especially in skeletal and 
cardiac muscle, and has a half-life over three times as long as the D 
form which was concentrated primarily in renal and hepatic tissue and 
to a lesser extent in heart, muscles, fat, duodenum, ileum, brain, 
adrenals, and testes. 
Dextrothyroxine has been shown to be more rapidly degraded and 
deiodinated, and therefore disappears more rapidly from the blood, than 
the levo-isomer. 149, 150, 151 Excretory mechanisms related to both 
levo- and dextrothyroxine have been reviewed by Arons. 152 
Calorigenic Effects: NaD-T4 
Determination of the anoxia survival time is one of the most use­
ful physiologic tests employed in measuring calorigenic activity of 
pharmacologic agents. In this test premedicated animals are placed in 
closed containers and their survival times com�red with a non­
medica�ed control group. A mean reduction in survival time in minutes 
ha s been established 'using mice premedicated subcutaneously for seven 
consecutive days with one, two, four, and eight micrograms of L­
thyroxine and 20, 40, 80, and 16 0  micrograms of D-thyroxine, 
respectively. The data are summarized in Table 4. * 
*Unpublished data on file in the Research and Development Department, 
Baxter Laboratories, Inc. , Morton Grove, Ill. 6 0053. 
u 
II: 
TABLE 4--Effects of D- and I-Thyroxine Upon the Anoxia Survival Time of Mice 
Premedieated Subcutaneously for Seven Consecutive Days. (E:ach 
Group Represents 15 Mice* )  
Mean reduction of 






















Mean reduction of 





*Unpublished data on file in the Research and Development Department, Baxter Laboratories,. 
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Toxicologic Studies: NaD-T4 
The natural thyroid hormones and sodium. salts of synthetic L­
thyroxine have been investigated in depth in several animal species 
including man. Very little is known, however, concerning acute 
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toxic ty of D-thyroxine in either laboratory animals or humans. The 
median lethal dose (LD50) of the sodium salts of both L- and D­
thyroxine have been determined, employing various routes of administra­
tion , only in mice (Table 5* ) .  Dextrothyroxine employed in acute 
toxicity s+udies was prepared as a solution in physiological saline 
for intravenous use or ns a suspension in phy iological saline con­
taining 10 per cent gum acacia for alternate parenteral or oral 
routes. 153 The median lethal dose of NaD-T4 in rabbits is unknown. 
It has been estimated, however, to be approximately 15 mg. /kg. if 
administered chronically. ** 
Comparative chronic toxicology of dextro- and levothyroxine in 
both rats and dogs has been reported in detail by Garvin tl !1• 154 
It is interesting to note that, based on data from these studies, 154 
a p.o. daj_ly dose of NaD-T4 as low as 20 mg. produced thyrotoxic 
symptoms in some rats, while p.o. daily doses of 1200 mg. were well 
tolerated in dogs. Dextrothyroxine was well tolerated by both rats 
and dogs at lo rer dosage levels. Experimental animals were normal in 
appearance , behavior, growth, and no significant macroscopic pathologic 
*Unpublished data on file in the search and Development Dep rtment, 
Baxter Laboratories, Inc. , Morton Grove, Ill. 60053. 
• R. M. Gasler, Ph . D. ;  Director of Pharmacologic Research, Baxter 
Laboratories , L�c. , Morton Grove, Ill. Pe sonal Commu ica tion. 
TABLE 5--Acute Toxicity of D- and L-Thyroxine in the Mouse• 
LD50 (mg. /kg. ) 
Isomer Route ** 24 hours 7 days 
D-Thyroxine i.v. Over 450 Over 450 
D-Thyroxine p.o. Over 16 , 000 Over 16 , 000 
D-Thyroxine i.p. Over 3 , 500 Over 3 , 500 
L-Thyroxine i.v. 475 475 
L-Thyroxine p.o. 16 , 000 16, 000 
L-Thyroxine i.p. 2, 500 2 , 500 
• Unpublished data on file in the Research and Dev,elopment Department, Baxter Laboratories, 
Inc. , Morton Grove, Illinois 6 0053 




lesions or deaths attributable to NaD-T4 occurred. Hemogram parameters 
remained within normal limits for both species during treatment periods. 
Microscopically, significant changes attributable to medication were 
observed only in rats. Histopathologic changes consisted of cardiac 
lesions varying from slight subendocardial inflammation to marked sub­
endocardial nec1·osis and repair. Renal changes noted were glomerular 
and juxtaglomerular arteriolar nephrosclerosis. Organ weight changes 
were noted in_ both rats and do gs medicated with sodium dextrothyroxine. 
Organ weight alterations were not associated with histopathology and 
· were considered dose dependent. 
MATERIALS AND METHODS 
A. Teratology: Stug.y 
Select on 2f. Experimental Animals 
Polytocous , virgin mammals were considered for use as experi­
mental animals in this study. Several criteria were evaluated before 
rabbits were chosen in preference to other possible species . Addi­
tional studies evaluating DT4 induced alterations in cholesterol 
metabolism during p egnancy will follow these investigations . There-
. fore, not only placental type, and gestation duration, but also 
susceptibility to cholesterol-induced atherosclerosip were evaluated 
when considering various species. 
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Canines and rats were eliminated as possible choices because both 
are normally resistant to experimentally induced hypercholesterolemic 
hyperlipemia. 155 Ra.ts show little teratogenic sensitivity .156 
Rabbits, however, are quite susceptible to pathological dyslipemias and 
teratogenic activity . 157 Increasing dietary cholesterol levels "rill 
cause a rapid and predictable hypercholesterolemic response in rabbits 
but not canines or rats . 1.58 Felines were eliminated because of theil• 
zonary rather than discoid and endothelial-choria.l rather than 
hemoendothelial type placentation. 
Rabbits utilized in this investigation were New Zealand White, 
virgin does - weighing three and one-half to four kilograms. Animals 
were ordered and received in a single shipment from one supply source. 
All animals received an extensive initial clinical examination and 
were found alert, active and apparently disease-free. 
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Experimental animals were individually housed in stainless steel 
batteries and maintained on a commercially available palletized rabbit 
diet* and ineral supplement**  ( T  ble 6 ) .  Feed and water were pro­
vided ad libitum. Animal quarters were air conditioned to minimize 
environmental temperature fluct 3tions. 
Treatment !,ru! Control Groups 
Following a 14-day post-delivery observation and adaptation 
period a table of random numbers was employed to randomly allocate 
animals to one of two experimental groups or the control group each 
containing ten does . New Zealand White bucks were employed for 
breeding. 
Control animals received 0.5 ml. of diluent each day of preg­
nancy. Does in Experimental Group I received two mg. of NaD- T4 in 0.5 
ml. of diluent each day of pregnancy. Animals in Experimental Group II 
received 0.5  ml. of diluent during the first 15 days of gestation and 
two mg. of NaD-T4 in 0. 5 ml. diluent daily the last 15 days of preg-
nancy . 
&bbits are typical induced ovulators. Cervical stimulation 
during coitus re��lts in neuronal LH release follo ed by ovulation in 
approximately 10 hours. Therefore,  hormone or  diluent administration, 
*Rabbit Family Ration ,  Albers Milling Co. , Los · Angeles, Calif. 
**Carey Mineral Supplement, Carey Salt Co . ,  St. Louis, Mo. 
TABLE 6--Chemical Analysis of Albers Family Ration Rabbit Pellets 
and Carey Mineral Supplement Spools With Salt 
A.  Albers Famil;y Ration Rabbit Pellets 
B. 
Guaranteed Analysis : 
Crude protein, not less than 
Crude fat, not less than • •  
Crude fiber, not more than . 
• • • • • • • • • • • • 
• • • • • • • • • • 
• • • • • • • • • • • • 
• • • • • • • • • • • • • 
• 18 . 0� 
• 12. oi Ash ,  not �ore than • • • • 
Vitamin A, not less than . • • • • • • 4000 u. s . P .  Units /lb 
Carey Mineral Supplement Spools � Salt 
Garanteed Analysis : 
Min. Phosphorus (P) 
Max. Calcium (Ca ) 
Min. Calcium (Ca) 
Min .  Iron (Fe ) 
Min. Manganese (Mn) 
Min. Copper (Cu) 
Min. Cobalt ( Co) 
Min. Iodine (I)  
Min. Zinc (Zn) 
Max . Salt (NaCl)  
Min . Salt (NaCl) 
2. 76oj 
3 . 500% 











calculated to begin on day one of gestation, .was administered the first 
24-hour period following this approximate lO�hour delay. 
Hormone Pre,n?r tion : Sktl Administration 
Hormone (NaD-1i�) employed in this study �s supplied as a fine, 
cream-colored powder having chemical and physical characteristics 
listed in Table 7 (Experimental Sample). 
Hormone preparation, in suitable media for oral administration, 
was unexpectedly difficult. Attempts to suspend the material in 
alkaline 1oi gwJ'l acacia solution as suggested by Gesler* were met with 
limited success. The suggestion by Palmer** to dissolve the hormone 
in hot ethanol adjusted to a moJerately alkaline pH with sodium 
hydroxide produced a suitable media. 
011e hundred ml. aquilots of solution containing 4 mg. NaD-T4/ml. 
were prepared weekly. The hormone was supplied as a hydrate 
(8. J6i HzO) . Tnorefore, a correction was made for this moisture level 
when ce.lculati.ng the 4 mg. /ml/ amount (4. J649 mg. of hydrate in 
solution equals 4. 0000 mg. NaD-T4/ml. ). 
The horrri.one hydrate (0.4J65 Gm. ) was �laced in a 100 ml. volu­
metric flask and 84 ml. of ethanol added during continuous shaking. 
Sixteen 1111. of O.lN .TaOH wore added slowly until the solution cleared. 
Temperature of flask and contents was elevated from 20°c. to 75°c ,  
*R. M. Gesler,  Ph. D. ,  DiTector of Pharmacologic P.esearch, Baxter Labs. , 
Inc. , Morton Grove, Illinois . Personal Com.'11ltlnication. 
**Ivan s. PnJxier,  Ph. D.,  Station Biochemistry, South Dakota St�te 
Unive sity , Brooi ings , South Dakota. Personal Communication .  
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TABLE ?--Chemical and Phys ical Properties of a Reference Standard and 
Experimental Sample of 3 : 5 : J ':5 ' -tetraiodo-D-thyronine 
A. Reference Standard 
Molecular Formula: 
Molecular Weight : 
So lu bili ty : 
Melting Point: 
Optical Rotation :  
Appearance : 
B. ExJ?et•imental Sample 
Molecular Formula 
Mol cular Weight: 
Solubility: 
Melting Point : 
C15H1004N14,Na. 
798.884 (anhydrous salt) 
o.2i in H20 ;  o. 4� in 95� ethanol 
2J5-2J6° c. 
ii5 = +5. 5° (C3 . lN NaOH:EtOH 1:2) 
Cream-colored powder 
c15H10O4NI4Na 
798.884 (anhydrous salt) 
0 .2% in H2o ;  0 . 4i in 95% ethanol 
2J5-2J6°c. (free acid) 
Optical Rotation: i5 = +5 . 0° (CJ, lN NaOH:EtOH 1:8 . J) 
Appearance: Cre m-colored powder 
F. DeA ,,  &ference No.:  1466-LBO-ll 
� �20 8 . 36 
� I 62 . 6  
i N 1. 6 6  
and maintained until tha hormone was completely dissolved then sealed 
and slowly returned to room temperature . 
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Fifty ml. aquilots of a solution containing 42 ml. of ethanol and 
8 m. of O. lN NaOH were .prepared fresh weekly . for administration to 
control animals throughout pregnancy and Experimental I animals during 
the first 15 days of gestation. 
Problems commonly associated with repeated passage of gavage tubes 
were eliminated by use of a tuberculin syringe for oral drug administra­
tion employing a technique previously described. 159 Possibilities of 
oral leakage and diluent induced gastric irritation were reduced by 
preparation or hormone solutions containing desired daily dosage levels 
in one-half ml. 
Collection g! � 
Unnnesthotizod progn�nt aoos were sacrificed on day 29 of their 
gestation periods by massive air embolism induced by cardiac puncture 
employing an 18 gauge needle. All animals were suppinated and immob­
ilized on a slatted small animal holding board. A mid-line incision 
from xiphoid to pubis provided for adequate exposure of gravid uterine 
horns and cesarean delivery of fetuses. The uterus was then examined 
for resorption points and placental tissue obtained for subsequent 
histological examination. 
F.ach viable fetus was numbe�ed, its total body weight recorded 
(to one-tenth of a Qn. ) ,  and then prepared for roentgenological e�ami­
nation. Examination for externally apparent congenital anomolies 
preceded actual dissection. Stomach contents. and tissue exudates of 
non-viable fetuses, if present, were submitted for bacteriologic 
examination following aseptic removal. 
Roentgenological Examination 2f Fetal Skeletons 
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A General Electric· MONARCH model ll-D-B6 X-ray machine was 
utilized in roentgenological analysis or fetal skeletons. Fetuses 
were grouped by litter ,  numbered, and affixed to squares of heavy 
paper by transparent tape* to permit anterior-posterior (AP ) body 
exposure and lateral skull exposure. A non-screen technique employing 
a HRT-E-1-2 type tube was selected for exposure of thick emulsion film 
plates•• placed directly below each fetal group. Exposure was for 
JO ma . /sec . at 100 ma. and 50 kv. p. 
Dissection Technique 
Hepatectomy - Cholecystectomy 
Micro-dissecting surgical instruments employing a desk model 
magnifier were utilized in all dissection procedures. 
Primary superficial incisions from sternal notch to umbilicus mid­
ventrally and from a point one centimeter posterior to the xiphoid 
process bilaterally freed four skin flaps which were isolated and 
pinned. The abdominal muscles and peritoneum ventral to the liver were 
ident�fied, transected and retracted. The live� and gallbladder were 
dissected and removed from the peritoneal cavity in six steps: 
1. The dorsal corder of th� falciform ligament was identified 
at the umbilicus, traced anteriorly to its diaphragmatic , 
attachment, - then transected with the round ligament (ligamentum 
tares) in its free edge. 
*SCOTCH brand transparent tape , Minnesota Mining & Manufacturing Co. 
•*ANSCO MONOPAK Emulsion No� J8C2710-0J-0733 , General Aniline Film Corp. 
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2.  The left hepatic lobe was partially retracted exposing the 
left triangular ligament. 'Ihis ligament was transected at its 
attachment to the central diaphragmatic tendon and dorsal 
surface of the left hepatic lobe . 
J. The coronary ligament was identified at its reflection from 
the dorsum of the right hepatic lobe and transected. 
4. The hepatorenal ligaments were isolated, identified and 
transected. 
5 .  The cholecystoduodenal ligament, surprisingly well developed in 
most of the animals, was transected freeing the liver except 
for vascular attachments which were then severed. 
6. The gallbladder was removed from the inforior surface of the 
right lobe by blunt dissection. 
The liver was removed from the body cavity, blotted on absorbent 
paper and weighed immediately on a Sartorius balance sensitive to one 
ten-thousandth gram. A small section was cut from the right lobe proper 
and placed in 10� fomalin solution. 
Nephre tomy 
The right kidney was removed from the abdomen in five steps: 
-1. The initial mid-ventral incision was extended on the right 
side to a point just superior to the iliac crest. 
2 .  The lumbar fasci was exposed and transected exposing a 
ell developed layer of pararenal (retrorenal) fat. 
J. Par� renal fat was incised and its underlying perirenal layer 
used as a cleavage plane . 
4 .  The peritoneum was then pushed forward and both poles were 
mobilized. 
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5 .  Actual nephrectomy was accomplished after exposing and severing 
the pedicle with its contained vessels and ureter. 
After weighing the entire orga was placed in 1oi formalin for 
subsequent use in preparation of histological sections. 
Cardiac Re oval 
Tho heart was removed from the thorax in six steps: 
1.  The thoracic cavity was opened by a transverse incision across 
the diaphragm at its midpoint. 
2 . The rib cage was transected from its inferior costal margin 
through the first rib bilaterally from a point on either side 
and about one and one-half cm. ventral to the vertebral colu..�n. 
J . The rib cage was elevated and parietal pleura and mediastinal 
contents freed from the internal, ventral, thoracic surface . 
4 .  The sternum was freed a.t the Angle of Lewis bilaterally and 
the bony thorax discar ed. 
5. The mediastinum was incised and the pericardium dissected from 
the heart and gre at vessels . 
6 .  All vascular connections were severed as close to the heart 
as possible and the orga11 removed. 
The excised heart was placed on a wax dissecting plate, the atria 
incised, and blood clots removed employing micro-forceps . The excised 
organ was then washed in a commercially avai�able , * polyionic , 
physiological irrigating solution (Table 8 ) �nd drained . The epi­
cardium was blotted on absorbent paper and wet weight (to one ten­
thousandth of a Gn.)  recorded .  
Dry weights were recorded to  one ten-thousandth or a Gm.  after 
desiccation , to a constant weight, in a vacuum oven set at JO psi 
vacuum and 65°c. 
Pneumonectom� (Right Lobectomy - Segmental Resection) 
Pneumonectomy was accomplished in four steps: 
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1.  The original thoracic incision was extended posteriolaterally 
to effect adequate rignt lung exposure. 
2 .  Hilar structures ere exposed in the mediastinum by sharp 
dissection of adjacent (mediastinal) pleura, anteriorly and 
superiorly. 
J .  Hilar structures were then isolated, mass ligated and tran­
sected . 
4 . Posterior mediastinal pleura was then incised and the lung 
removed. 
The excised lung as blotted on absorbent paper and wet weight 
(to one ten-thousandth Gm.) recorded. Apical lung tissue was then 
resected and pl ced in 10% formalin for subsequent histological 
sectioning and examination. 
*TIS-U-SOL (Physiological Irrigating Solution), Baxter Laboratories, 
Inc. ,  Morton Grove, Illinois. 
TABLE 8--Chemical Composition of TIS-U-SOL, * a Commercially 
Available Physiological Irrigating Solution 
EACH 100 ml. CONTAINS : 
800. 00 mg. Sodium Chloride, U . S.P. 
40. 00 mg. Potassium Chloride, u . s . P .  
20. 00 mg. Magnesium Sulfate • 7Hz0 , u . s . P. 
a .75 mg. Sodium Phosphate, Dibasic • 7Hz0 , u .s .P .  
6.25 mg. Potassium Phosphate, Monobasic 
100. 00 mg. �xtrose (HYDROUS) , u. s .P. 
MILLIEQUIVALENTS PER LITER: 
137 . 6  mF.q. Sodium 
5 .8 mEq. Potassium 
1 .6 mF,q. Magnesium 
142 . J  m�. Chloride 
1. 6 mF,q. Sulfate 
1. 1 m&J_. Phosphate 
* Baxter Laboratories, Inc. , Morton Grove , Ill. 
Histological Methodologz 
Fatal tissues selected for histologic examination included liver, 
lung and kidney. Placental tissue and maternal heart tissue from each 
control  and experimental doe were also examined. 
Placental and maternal heart tissue were placed in labeled low 
jars containing 250 ml. of 1oi formalin immediately after animals were 
sacrificed. Organ tissues from each fetus were grouped in labeled 
four dram vials and fixed in 10% formalin following dissection pro­
cedures. 
All maternal heart and placental tissue samples were examined 
microscopically. Two fetuses were selected at random from each con­
trol and experimental litter for microscopic analysis of liver, 
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kidney and lung tissue. Three slides were prepared from two rectan­
gular section� of each fetal organ. Tissues were trimmed to expose a 
cross-sectional surface with a minimum of tissue trauma and/or compres­
sion. 
Procedures utilized in washing, dehydrating, clearing and embed­
ding tissues ar_e summarized in Table 9 .  Tissue mounts were cut seven 
microns thick , collected in ribbon form and refrigerated until mounted 
on slides and stained. Staining procedures are summarized in Table 10. 
Microscopic examination validated removal of tissue sections from 
Harris Hematoxalin, acid alcohol,  tap water and Erythrosin B counter­
stain. Chemical composition of reagents employed in staining pro­
cedures are listed in Table 11. 
Analysis 2f. Fetal Organ Weight � 
An IBM ;60 model 30 computer was employed for statistical analysis 
of data . Raw data punched on IBM cards for computer use included: 
treatment or control group number, doe number, fetal animal and total 
body weight, wet/dry hea rt weight and wet liver, right kidney and right 
lung weights. All organ weights were recorded to one ten-thousandth 
gram employing a Sartorius be.lance. 
TABLE 9--Procedures Utilized in Preparation of Maternal 
and Fetal Tissue Samples for Sectioning 
Procedure Ihration Reagents 
Washing 24-72 hours 70% ethyl alcohol 
Dehydrating 60 minutes 80% ethyl alcohol 
Dehydrating 60 minutes 9oi ethyl alcohol 
De hydra ting 30 minutes Absolute ethyl alcohol 
Clearing 30 minutes Absolute ethyl alcohol 
and xylol (1 : 1  ratio) 
Clearing 30 minutes Xylol 
Infiltration 30 minutes Xylol and melted 
paraffin (1:1 ratio) 
Infiltration 120 minutes Paraffin bath I 
Infiltration 12 hours Paraffin bath II 
Block mount 
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TABLE 10--Procedures Utilized in Staining Maternal 






9oi ethyl alcohol 
80% ethyl alcohol 
70% ethyl alcohol 
Distilled water 
Harris Hematoxylin 
Distilled wa tar 
Acid alcohol (5oi) 
Tap water 
Distilled ater 
70% ethyl alcohol 
aoi ethyl alcohol 
Erythrosin B 












6 0  seconds 
























Stain plasma embranes 
and nuclei 
Excess stain removal 
Excess stain removal 
Excess stain. removal 









Mount cover slip 
TABLE 11--Chemical Composition of Reagents Employed in Staining 
Maternal and Fetal Sections 






Absolute ethyl alcohol 





5oi absolute ethyl 
alcohol 
Concentrated HCL 
0 . 5  Gm. 
5.0 ml. 
10. 0 Gm. 
95 . 0 ml. 
0. 3 Gn. 
100. 0 ml. 
1. 0 Gm. 
100. 0 ml. 
1. 0 ml. 
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The relationship between total fetal body weight and selected 
organ weights was linear. Therefore, computed regression coefficients 
were employed to adjust all raw organ weight data prior to final 
analysis . 
Analyses of variance on adjusted organ wei ghts was the statistical 
method used to interpret all final data. 
Examin - tion of Fetuses fs?.1: Anomalies (Terata ) 
All fetuses delivered were single individuals. There were no 
instances of diplopagi (conjoined double-monster-complete twins ) .  
symmetrical conjoined twins ( gemini monochorii aequales ) or asymmetrical 
conjoined twins (gemini monochorii inaequales ). - No cases were found in 
the body (fetus 1n, �), skin (dermocyma ) or body wall (endocyma) of 
an autosite fetus. 
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Each control and experimental fetus wa s examined externally, 
internally and/or roentgenologically for anomalies {terata ) lis ted 
in Table 12. 
TABLE 12--Checklist of Anomalies (Terata ) Employed in Examination 
of Control and Experimental Rabbit Fetuses 
Type or Parts Involved 
I. Affecting the whole , or nearly 
the whole, body: 
A. Exces sive size 
B. Markedly small 
c. Di screpancy of size of lateral 
halves of body 
D. Markedly altered form 
II. Affecting regions , parts ,  or organs: 
A. Cranium and contents: 
1. _ Cleft or fissure 
2 .  Complete or  partial absence 
3 . Cleft with protrusion of meninges 
4. Cleft with protrusion of brain 
5. Cleft with protrusion of 
meninges and brain 
6. Herniation of brain with fluid 
in ventricles 
? • Herniation of brain with fluid 
in meninges 
8 .  Complete absence of brain 
9. Abnormally small cranium 
10. Abnormally shaped cranium 
11. Occipital cleft (cranium.) 



















Type or Parts Involved 
B. Spine and spinal cord: 
1.  Cleft or fissure of spine 
2 .  Cleft vi.th herniation of meninges 
J .  Cleft with herniation of spinal 
cord 
4 .  Cleft with herniation of meninges 
and spinal cord 
5 . Cleft of entire cranium and spine 
6. Absence of spinal cord 
C. Face and sense organs : 
1. Major ethmoidal region defect 
2 .  Complete or partial fusion of 
orbits and oyes 
J .  Marked nasal defects 
4. Absence of eyes 
5. Absence of eyelids 
6. Absence of nose 
7. Absence of mouth 
8 .  Absence of eyes, nose and mouth 
9. Absence of teeth 
10. Absence of tongue 
ll. Absence of lower jaw 
12 . Approximation of ears 
lJ . Abnormally small eyelids 
14. Abnomally small mouth 
15. Abnormally large mouth 
16.· Abnormally small ears 
17 . Abnormally small lower jaw 
18 . Abnomally large lower jaw 
19. A normally small teeth 
20.  Abnormally large teeth 
21. Abnormally small tongue 
22 . Abnormally large tongue 
2J . Clefts of face and jaws : 
a .  Palpebral fissure to nasal 
cavity 

































Type or Parts Involved 
c. Face and sense organs : 
2J. Clefts of face and jaws : 
b. Palpebral fissure to 
philtrum of lip 
c .  Mandibular joint to 
angle of mouth 
d. Vertical cleft of one 
both eyelids 
e. Clef't nose 
f.  Cleft lip 
g. Cle£t jaw 
h.  Cleft palate 
or 
i. Cleft  lip, jaw , and palate 
j. Cleft tongue 
24. Median cleft or fissure of neck 
below jaw 
D. Thorax and c ontents : 
1. Median cleft or fissure 
2. lateral cleft or fissure 
J. Median cleft with herniation 
of heart 
4.  Transposition of thoracic viscera 
5. Herniation of abdominal viscera 
into thorax 
6 . Cardiac transposition 
E. Abdominal-pelvic cavity and contents: 
1. Cle ft or fissure of abdomen 
2 .  Hernias 
a. Into umbilical cord 
b. Through lumbar triangle 
c. Through inguinal region 
Name or Example 
Type II Oblique 
:facial cleft 
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Gna tho s c h_is is 
Pala toschisis 
Cheilognatho-
pala tos h.isis 













Type or Parts Involved 




Anomalies of G.I. Tract 
a .  Ma.lpositions 
b. Muscle hypertrophy 
c. Sac cula tions 
(1) Stomach 
(2 ) n.todenum 
(3)  Jejuno-ileum 
(4 ) Patent vitelline 
(5 ) Large intestine 
Intestinal obstructions 
a. Intestinal atresia 
b. Maconium aggregations 
c. Volvulus 
d. Imperf orate anus 
Pelvis and contents: 




b. Cleft or fissure of pelvis 
c. Pelvic cleft with extro­
version of bladder 
d. F.actum opening into bladder 
F. Extremities : 
1. Congenital absence of all 
extremities 
2. Congenital absence of at least 
one but not all extremities or 
their imperfect development 
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Meckel ' s  diverticulum 
Diverticulotic 
appendices epiploicae 
Discontinuity of lumen 
Meconium ileus 
Torsion of cecum or 
sigmoid 









Type or Parts Involved 
F. Extremities : 
J .  Distal portion of limbs absent 
or markedly deficient 
4. Proximal portion of limbs absent 
or markedly deficient 
5.  Limbs normal but abnormally small 
a. Fore limbs only 
b. Hindlimbs only 
6. Medial rotation and fusion 
of hindlimbs 
a.  With feet lacking 
b. One foot present 
c .  Two feet pre sent 
d. Skin only between limbs 
? . Complete or partial absence of 
one or ore digits 
8. Abnormally s hort digits 
9. Abnormally long digits 
10. More than normal number of digits 
11. Fusion of digits (complete) 
12 . Skin web between digits 
lJ. Hypertrophy of forefoot 
14. Hypertrophy of hindfoot 
15. Partial duplication of forefeet 
16. Distortion of forefeet 
l? . Distortion of hindfeet 
B. Efficacy Studx : NaD-T4 























In addition to teratogenic activity, cholest�ropenic efficacy of 
NaD-T4 in New Zealand White rabbits was screened. Animals utilized in 
the efficacy study were virgin does weighing two to four and one-half 
kilograms. All rabbits were housed individually in air conditioned 
animal quarters to minimize environment.al temperature fluctuations. 
Fol owing a two-week adaptation period a table of random numbers 
was employed to assign animals to either the treatment or control 
group each containing five does. Hypercholesterolemic hyperlipemia 
was provoked in both treatment and control animals by feeding a com­
mercially available palletized rabbit diet containing two per cent 
choles 0rol. *. Feed� water and mineral supplement** were provided !2_ 
libitum during tha 21-day study period. Blood was obtained from all 
animals a total of three times : 
l. Prior to initiation of two per cent cholesterol diet (Day 1)  
2. The first day of drug or saline administration (Day 14) 
J .  The last day of drug or saline administration (thy 21). 
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Treatment group animals received 2. 0 mg. of NaD-T4, orally, daily for 
seven days. eypercholesterolemic control group does received an equal 
amount of Normal Saline during the same period. Hormone preparation 
and oral administration techniques were identical to those already 
describede 
Unanesthetized animals were suppinated and i.¥fmlobilized on a �latted 
small animal holding board. The thorax was shaved and painted with an 
aqueous solution of 1 :750 benzalkonium chloride before 10 ml. of blood 
was drawn by cardiac punc ture employing aseptic techniques. A 20 gauge 
needle was used to minimize hemolysis. Refrigerated whole blood was 
•2i Cholesterol Diet 9 Nut.ri tional Biochemicals Co. , Cleveland, Ohio . 
* *Carey Mineral Supplement, Carey Salt Co. ,  St . Louis, Mo. 
allowed to clot for two hours and then centi--ifug�d at JOOO rpm for JO 
minutes. Serum obtained was decanted and quick frozen until analyzed 
for total cholesterol at a later date. 
Determination of Total Serum Cholesterol (Qlrect Method) 
Cholesterol is soluble in many organic medias including ether, 
chloroform, acetic anhydride and acetic acid. Differing but character­
istic solubility patterns in these various media have led to many 
techniques for isolation and separation of cholesterol from whole blood 
and numerous blood fractions. A modification of the Schoenheimer­
Sperry Methodl60 was employed in this study. 
• A commercially available , stable, Lieberman-B.irchard reagent was 
employed for total serum cholesterol detennina ions. Reagent stability 
is apparently achieved by a process of compounding 14. 5% sulfuric acid 
in 41.0% acetic acid and 4J. O% acetic anhydride under controlled 
temperature conditions. Use of this reagent results in a reaction 
specific for the double bo�d between c5 and C6 on ring B of the sterol 
molecule producing a typical green-blue color. 
Ti.med sequence of reaction rates was not considered important 
since readings made within 10 minutes following color development were 
always stable. All samples were read within this time period employing 
a Beckman Model DB-G spectrophotometer. Absorbance characteristics of 
the re action at 625 mu followed Beer-I.Ambert ' s  I.aw. 
*Hycel Cholesterol F.ea gent , Hycel, Inc., Houston, Texas. 
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A. Methodology 
1. Accurately pipette 0.1 ml. of serum into marked cuvette. Place 
0. 1 ml. cholesterol standard into marked cuvette. 
2. To each test tube or cuvette add 6 .0 ml. cholesterol reagent. 
Mix well by shaking. 
J. Place cuvett.es in ater bath at 37°c. for 20 minutes. 
4. Read optical density against reagent at 625 mu. 
�. Calculations 
l. "A" - Optical density of unknown 
2. "B" - mg. %  value of control or standard 
J .  "C" - Optical density of standard or control· then ; 
A X B mge %, Unknown 
Table lJ indicates reproducibility of the Liebermann-furchard color 
reaction employing eycel stable cholesterol reagent in analysis of 20  
"standard" cholesterol samples in three concentration ranges. 
Use of a stable reagent with a high specificity of reaction lends 
itself to a relatively simple methodology. However, the question of 
color development produced by blood constituents other than cholesterol 
is possible if bilirubin levels are highly elevated or considerable 
hemolysis is evident. Elevated bilirubin levels did not occur in either 
experitdental or control animals used in this study and precautions were 
taken to minimize hemolysis when blood was collected . Adherence to 
accepted laborato1-y technique decreased the possibility of inadvertent 
transfer of red cells with serum samples or addition of moisture to 
TABLE 13--Reproducibility of the Liebermann-:atrchard Color Reaction Employing 
Hycel Stable Cholesterol Reagent 
Concentration No. 
of standard determinations Average Std. Dev. Range 
-
100 mg.%  Standard 20 100. 1 mg. i  :tl. 3 mg. 1, 97 - 103 mg. % 
200 mg. % Standard 20 199 .8 mg. � +2. 3 mg. � 195 - 205 mg. i 
JOO mg.� Standard 20 J00. 4 mg. � :t,. 5 mg. �  290 - 310 mg . �  
$ 
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reaction mixes. Such errors could falsely elevate apparent cholesterol 
values. If it had been necessary to use serum showing significant 
hemolysis, values would have been rechecked using an alcoholic extract. 
RESULTS AND CONCIDSIONS 
A. Teratology Study : · NaD-T4 
Fetal Death 
No type of macroscopic uterine pathology, such as endometrial 
hyperplasia , myomata , or pyogenic infection, was observed in either 
control or experimental does. 
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Data were obtained from 59 control9 63 Experimental I, and 56 
Experimental II fetuses . Table 14 shows nu..�ber  of pregnant does , total 
number of fetuses obtained, intrauterine mortality rates (%) ,  and 
approximate age in days of non-viable fetuses found _ in each animal 
group. Tissues , stomach contents and body fluids of non�viable fetuses 
were submitted for bacteriologic examination immediately following 
aseptic removal from the uterus on day 29 of gestation. No bac­
teriologic growth was obtained from these specimens . •  In every case , 
duration of sterile intrauterine autolysis in experimental does was 
estimated at 24 - 48 hours. 
Oral NaD-T4 in daily does of 2. 0 mg. had no significant effect 
on intrauterine mortality rates , when compared to control animals , if 
administered during the last half of pregnancy. However, an increase 
of over 20� in intrauterine mortality, at the same daily p. o.  dosage 
level, was noted follo·.dng initiation of therapy on day one of ges­
tation . Observed discrepancies in embryotoxicity, were attriblted, 
• AnL�al Disease Research and Dia gnostic Laboratory, Brookings , s. D. 
TABLE 14--0bserved Embryopathies in 29 Day Rabbit Fetuses 
Non-Viable Fetuses 
Animal Fetuses :  
group NCi total no. Number % of total 
Control4 8 59 2 
Experimental lb 9 63 15 
Experimental IJ:C 7 56 2 
4No drug (Dextrothyroxine) administered. 
bz . o  mg. NaD-T4 administered p.o. daily each day of gestation. 
02. 0 mg. NaD-T4 administered p.o. daily last 15 days of gestation. 
0Number of pregnant does. 





10 - 12 
27 - 28 
27 - 28 
V\ 
N 
therefore , to variations in time of drug administration and not 
differences in dosage form. Increased dpe lethality did not occur 
in experimental animal groups at the 2.0 mg. p. o .  daily dosage level 
employed. 
Analysis 2f. Fetal Organ Wei�hts 
Fetal parameters analyzed statistically included total body 
weight, wet/dry heart, wet liver, and et right kidney and lung 
weights. Raw data are listed in appendix Tables 1 through � 
Organ weights were recorded to one ten-thousandth gram. 
Compensation for expected variation in organ weights between 
individual animals within control or experimental groups, caused by 
individual animal total body weight differences, was accomplished by 
use of computed regression coefficients to adjust raw data prior to 
analysis. Table 15 lists mean - eights, in grams, of fetal organs 
selected fo·r statistical analysis. 
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Analyses of variance on adjusted organ weights was the statistical 
method -employed to interpret all final data . Statistical results are 
summarized in Tables 16 through 20. Organ weight data were obtained 
only from fetuses judged viable following cesarean delivery. 
Dramatic increases in all organ weights monitored were noted in 
fetuses obtained from does administered NaD-T4 in 2 . 0 mg. p . o. daily 
doses during either the terminal half or throughout the entire ges­
tation period. Results of statistical analysis indicated highly sig­
nificant treatment effects (fetal organ weight increases) in both 
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TABLE 15--I.east Squares Means : Selected Fetal Organ Weights ( Qn. ) 
Fetal Organ Mean Animal 
group* weight (Gu.)  
Wet Heart Weight 
Dry Heart Weight 
Liver 
Kidney Weight (rt .)  
























j . 2428 







*Ex I • • • • • •  2 . 0  mg. NaD-T4 p. o. /daily each day of gestation 
Ex II • • • • • 2 . 0  mg. NaD- T4 p. o. /daily last 15 days of gestation 
Contxol • • •  No Na.D-T4 adn1inistered during gestation 
experimental animal groups. Absolute increases in all organ weights 
monitored were greater, however, in fetuses from Experimental I does 
who received the drug daily during pregnancy. 
It is reasonable to assume that NaD-T4 like parent thyroid hor­
mones, traverses the placental barrier. Effects of repeated exposure, 
route of administration of dosage form on distribution and concentration 
of dextro thyroxine in fetal and /or placental tissue remain unknown. 
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TABLE 16--Analysis of Variance : Fatal Wet Heart Weights 
Sum of Mean 
Source d. f. squares squares "F" 
Total 1.58 7 . 9105524 
Treatment 2 . 0298743 . 0149372 8.439** 
Error 156 . 2761075 . 0017699 
••p 0. 01 
TABLE 17--Analysis of Variance : Fetal Dry Heart Weights 
Sum of' Mean 
Source d.f .  squares squares "F" 
Total 158 .1598035 
Treatment 2 . 0003499 . 0001749 5 . 598 **  
Error 156 . 0048762 . 0000312 
**p 0 . 01 
TABLE 18--Analysis of Variance : Fetal Liver Weights 
Sum of Mean 
Source d . f. squares squares "F" 
Total 1.58 1496 . 1048 
Treatment 2 19. 2730 9. 6365 29. 832**  
Error 156 50 . 3925 . J2JO 
••p 0. 01 
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TABLE 19--Analysis of Variance: Fetal Kidney Weights 
Sum of Mean 
Source d.f. squares squares "F" 
Total 1.58 5. 123988 







* *p 0.01 
156 . 118556 .0007599 















Therefore, definitive studies, similar to those of Tapley et al.,144 
employing lJl1-tagged dextrothyroxine are necessary to elucidate its 
distribution patterns and concentration in these tissues. 
Possibility of treatment and/or control organ weight errors intro­
duced by invalid or inconsistent dissection techniques is minimal. 
Detailed, sequential, and standardized dissection techniques were 
established prior to collection of experimental data and rigidly 
followed during each dissection procedure. 
Multiple morphologic alterations observed in fetuses obtained from 
treatment group does are attributed directly to dextrothyroxine 
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administration. Contamination of NaD-T4 employed in this investigation 
with its L-isomer is most unlikely. Chemical and physica l character­
istics of the available sample (Table ? )  attest to its purity. Absence 
of marked calorigenesis and clinical symptoms of catecholamine syn­
ergism in treated animals eliminates gross NaI.- '14  contamination as a 
possible causal factor in explaining observed fetal organ weight altera­
tions. Further, effects of minute L-isomer contamination would con­
tribute only to observed increases in fetal heart weight. 
The possibility of developmental (morphologic) idiosyncrasies, 
such as fetal organ weight alterations, resulting from placental 
transfer of bile acids and related cholesterol degradation products 
should be investigated in hypercholesterolemic animals. Although 
c edible in theory, the practical importance of such a mechanism is 
doubtful considering the highly significant increases in fetal organ 
weights observed in this investigation when utilizing euthyroid, 
normocholesterolemic does. 
Gross !IE. Roentgenological Examination 2f. Fetuses f21: Anomalies 
All control, Experimental I and Experimental II rabbit fetuses 
were critically examined for embryotoxic and/or teratogenic effects 
following cesarean delivery on day 29 of gestation. Fetuses were 
examined externally, internally. and roentgenologically for anomalies 
(terata ) listed in Table 12. Ra.diographs of typical control and 
experimental rabbit fetuses are illustrated in Fig. 1 - 3. 
P) of 29 dav control rabbit fetuses. No skeletal abnormali­
rent 
'i£ 
h (A-P) or 29 day 
lities are apparent. 
r1mental I rabbit fetuses . No skeletal 
g� )-aRadiogra.ph (A�P) or 29 day Experimental II rabbit tetuses . No skeletal 
.bnormalities are ap)'.)8.rent. 
� 
All fetuses delivered were as single individuals. There were 
no instances of conjoined double-monster-�omplete twins, symmetrical 
conjoined twins or asymmetrical conjoined twins . No cases were found 
in which an omphalosite embryo was located in the body, skin or 
parietes of an autosite fetus. 
Every fetus obtained during the study, from both control and 
experimental group does, was judged free of listed embryotoxic and/or 
teratogenic �nomalies after exhaustive examin�tion. 
Histologic Examination of Selected Fetal !n,g, Maternal T�s ues 
Two fetuses were selected at random from each control and experi­
mental litter for microscopic analysis of liver,  kidney and lung 
tissue. Placental tissue and maternal heart tissue from each control 
and experimental doe were also examined microscopically. 
Detailed histologic examination followed preparation of three 
slides from duplicate blocks of each selected tissue. All blocks 
were cut seven microns thick and stained with Harris Hematoxylin and 
Erythrosin B counterstain. 
No histopathology was expected or observed in placental tissue 
or maternal heart sections. Further, liver, kidney and lung tissue 
obtained from control fetuses were judged normal. 
No microscopic changes attributable to medication of pregnant 
does with sodium dextrothyroxine were observed in tissues obtained 
from either Experimental I or Experimental II fetuses. Active 
hemopoiesis was evident in sinusoids, often packed with proerythro­
blasts and erythroblasts , of all fetal liver sections examined. 
Renal lesions observed in non-pregnant rats following chronic 
administration of NaD-T4145 , 1.54 did not develop in experimental 
rabbit fetuses . No instances of arteriolar nephrosclerosis ,  involving 
glomeruli or juxtaglomerular cortical tis sue areas ,  were observed. 
Increased liver , kidney and lung weights observed in fetuses 
obtained from does medicated with sodium dextrothyroxine were not 
a s sociated with significant microscopic alterations or histopathology. 
Observed fetal organ weight differences were shown to be highly 
significant for both gro ps of experimental fetuses. However, mean 
organ weight changes appeared proportional to _duration of drug admin­
istration. 
B. Efficacy Stu,QY: NaD-T4 
Total �rum Chole sterol Values 
Hypercholesterolemic hyperlipemia was provoked in ten New Zealand 
White virgin doe rabbits, divided equally into a control and treatment 
group, by !,g_ libitum feeding of a two per cent cholesterol diet . 
Blood �as obtained from all animals a total of three times during 
the 21-day study period : 
1 .  Prior to initiation of two per cent cholesterol diet (Day 1) 
2 .  The first day of drug or saline admini stration (Day 14) 
3 . The last  day of drug or saline administration (Day 21). 
Treatment group animals received 2 .0 mg. of NaD-T4 p.o .  daily for 
seven days . Hypercholesterolemic control . group does received an equal 
amount of Normal Saline during the same period. 
Data obtained from analysis of total serum cholesterol in blood 
drawn from both control and treatment animals on each sample day are 
listed in Table 21. Table 22 summarizes differences in cholesterol 
levels (mg. �) noted between bleeding dates for each animal and tends 
to verify expected biologic hypocholesterolemic efficacy of sodium 
dextrothyroxine in rabbits. 
Cholesterol levels of control animals maintained on the experi­
mental diet for 21 days showed a mean increase of . 405 . 5 mg. �  during the 
study period . Animals maintained on the same dietary regimen for 
identical periods but treated during the terminal seven days of the 
study period with 2. 0 mg. NaD-T4 p.o .  daily exhibited mean increases 
in cholesterol levels, above initial values, 171 . 7  mg.% less than 
controls. Fig.  4 illustrates appearance of serum obtained from 
normocho1esterolemic, s light hypercholesterolemic and marked hyper­
lipemic animals. Serum in tube "B" (Fig. 4) was obtained from a 
rabbit ainta.ined on a high cholesterol diet and treated with 2 . 0 mg. 
NaD-T4 p.o.  daily. Total serum cholesterol level was 198. 6 mg. i. 
Serum from tube C" (Fig. 4) was obtained from a hypercholesterolemic 
control doe (no NaD-T4) maintained on a two per cent cholesterol diet 
for 21 days prior to bleeding. Total serum cholesterol level was 
579 .6  mg.�. 
TABLE 21--Total Cholesterol Values (mg. i) of Control and Treatment Animals Grouped By 










(cholesterol - mg.%) 
Day 1c Day 14d , Day 218 
66.7 197 . 6  464. 6 
90. J 171.2 516.0 
74.8 218.7 429.7 
.59. 1  161.4 477 . 6  
68 . 6  247.9 499. 1  
71.9 199.4 477. 4  









aTwo per cent cholesterol diet - no dextrothyroxine administration 
Treatment Animalsb 









bTwo per cent cholesterol diet plus 2. 0 mg. NaD-T4 p.o.  last seven days of study 
CPrior to initiation of two per cent cholesterol diet 
dThe first day of drug or saline administration 
8The last day of drug or saline administration 
Oly 21 
297.4 






TABLE 22--Differences (mg.%) Between Initial (Day 1), Day 14, and Terminal (Day 21) Total Serum 
Cholesterol Values Obtained From Control and Treatment Group Animals Showing Mean and 
Std. Error 
Control Animalsa Treatment Animalsb 
(cholesterol - mg. % difference) (cholesterol - mg. %  difference ) 
Animal no. Day 1-14 Day 14-21 Day 1-21 Day 1-14 Day 14-21 Day 1-21 
1 . 130. 9 267 . 0  397.9 188.4 37.8 226 .2 
2 80.9 344.8 425.7 170.9 92.5 26 3.4 
3 143.9 211.0 354. 9 122.9 73.8 196. 7 
4 102.3 316.2 418.5 125.9 135.3 261.2 
5 179.3 251.2 430 . 5 132.5 89.2 221.7 
MEAN 127.5 278.0 405.5 148.1 85.7 2JJ.-8 
Std. Error 16 .9 23.7 lJ.8 13.3 15.7 12.7 
. 
a Two per cent cholesterol diet - no dextrothyroxine administration 






New Zealand White rabbits, polytocous mammals susceptible to 
both pathological dyslipemias and teratogenic activity were selected 
for use in evaluating possible teratologic potency of orally adminis­
tered sodium D-thyroxine . Animals selected for use were alert, active 
and apparently disease-free virgin does weighing three and one-half 
to four kilograms . Rabbits were individually housed in wire mesh 
hutches and maintained on a commercially available palletized diet and 
mineral supplement . Feed  and water were provided !9_ libitum. 
Following a 14-day post-delivery observation period does were 
bred to· New Zealand White bucks and randomly allocated to one of two 
experimental groups or the co-ntrol group each containing 10 animals. 
The dextrorotatory isomer of thyroxine, as the sodium salt, was 
supplied in pure form as a fine cream-colored powder (NaD-T4) .  
Aquilots of hormone solution ( 4. 0  mg. NaD-T4/ml. ) were prepared by 
dissolving the salt in hot ethanol adjusted to a moderately alkaline 
pH with sodium hydroxide . 
Aquilots of a solution containing 42. 0 ml. of ethanol and 8. 0  ml. 
of O.lN NaOH were prepared as needed for administration to control 
animals throughout pregnancy and Experimental II does during the first 
15 days of gestation. 
Control animals received 0. 5 ml. of diluent each day of pre gnancy. 
Animals in Experimental Group I received 2 . 0  �g. of NaD-T4 in 0 . 5 ml. 
of diluent each day of pregnancy. Does in Experimental Group II 
received 0.5 ml. of diluent during the first 15 days of gestation and 
2. 0 mg. of NaD-T4 in o . ;  ml. diluent daily the last 15 days of preg-
nancy. 
Unanesthetized pregnant does were sacrificed on day 29 of their 
gestation periods by massive air embolism induced by cardiac puncture. 
Uterine horns were examined for resorption points and gross pathology 
immediately after cesarean delivery of fetuses. ¥..a.croscopic uterine 
pathology wa � not observed in control or experimental does. Nineteen 
non-viable fetuses were undergoing sterile intrauterine autolysis when 
removed from the uterus on day 29 of gestation. Data were obtained 
from 56 control, 48 Experimental I and 54 Experimental II viable 
fetuses. Increased doe lethality did not occur in experimental animals 
at the 2 . 0  mg. p.o. daily dosage level of NaD-T4 employed. 
Intrauterine mortality rates were similar in control and Experi­
mental II animal groups. Non-viable fetuses, expressed as a per cent 
of total was J .J8% for control and J . 57� for Experimental II does. In 
Experimental I animals the number of non-viable fetuses (15) represented 
2J.80% of the total. Observed discrepancies in embryotoxicity, at the 
same daily p.o. dosage level, were attributed to chronic fetal exposure 
during a more susceptible developmental stage early in gestation. 
All fetuses delivered were single individuals. There were no 
instances of abnormal twinning. Fetuses were examined externally, 
internally, and roentgenologically for over 100 primary pantasomatous 
and merosomatous terata.. Exhaustive examination of every fetus 
obtained in the study failed to uncover a s�gle anomaly. Sodium 
dextrothyroxine , in light of available data, cannot be considered an 
effective teratogenic agent. 
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Organ weight data including wet/dry heart, wet liver and wet right 
kidney and lung weights were obtained from fetuses judged viable 
followL�g cesarean delivery. P.esults of statistical analysis indi­
cated highly significant treatment effects (fetal organ weight 
increases) in both Experimental I and II animal groups. Absolute 
increases were greater in Experimental I doe fetuses who were exposed 
to the drug daily. 
No histopathology was observed in placental- tissue or maternal 
heart sections obtained from each control and experimental doe. All 
fetal liver, kidney and lung tissue sections were judged nomal. 
Increased liver, kidney and lung weights observed in fetuses obtained 
from does medicated with sodium dextrothyroxine ware not associated 
with microscopic alterations or histopathology. 
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APPENDIX 
APPENDIX TABLE 1- Total Body Weight and Selected Organ Weights (Gm. ) of 29 Day Control Rabbit 
Fetuses Showing Ratio Wet Heart/Kidney Wt., Mean and Standard Error 
Doe C#l Body Heart · Heart Ratio 
fetus no . wt . wet dry Liver Kidney lllng wet heart/kidney wt . 
1 46. 2 0. 2361 0. 0286 3. 1747 0. 2196 0. 6715 1.0751 
2 38. 6 0. 2451 0. 0270 2. 5567 0. 1772 0. 5185 1. 3831  
3 46. 1 0. 2601 0. 0300 3. 1549 0. 1844 0. 5588 1. 4105 
4 46. 9 0. 2340 0. 0286 3. 8904 0. 1933 o. 41.J.20 1 . 2105 
5 44. 3 0. 2290 0. 0291 3. 7266 0. 191 5 0. 4960 1. 1958 
6 45. 2 0 .. 2 538 0. 0287 3. 9055 0. 1708 0. 6819 1. 4859 
7 37.4  0 . 1691 0 . 0209 2. 6472 0. 1343 0 . 3702 1. 2591 
8 37. 1 0. 1847 0. 0226 2. 7552 0. 1258 0. 4265 1. 4682 
Mean 42. 7 0. 2264 0 . 0269 3. 2264 0. 1746 0 . 5206 1. 3110 
S . E. 1. 5 0. 0100 0. 0000 0. 1964 0 . 0100 0. 0387 0. 0519 
APPENDIX TABLE 2- Total Body Weight and Selected Organ Weights (Gm. ) of 29 Day Control Rabbit 
Fetuses Showing Ratio Wet Heart/Kidney Wt. , Mean and Standard Error 
Doe C#2 Body Heart Heart Ratio 
fetus no. wt. wet dry Liver Kidney Lung wet heart/kidney wt. 
1 42. 3 0. 1985 0. 0213 2. 9799 0. 1786 0. 6999 1. 1114 
2 36.2 0. 1687 0. 0193 2 .8380  0. 1735 0. 7459 0. 9723 
3 35. 6  0. 1933 0. 0204 2.2843 0. 1451 0. 5603 1. 3321 
4 J8. 5 0. 1815 0 . 0191 2. 4373 0. 1426 0. 5752 1.2727 
5 37. 4 0. 1833 0. 0192 2 . 8802 0 .. 1584 o. 6641 1. 1571 
6 JJ.2 0.2092 0. 0219 2. 1863 0. 1178 0 . 5353 1. 7758 
Mean 37.2 0. 1890 0. 0202 2. 6010 0 . 1526 0. 6301 1.2702 
S . E. 1 . 3 0. 0000 0. 0000 0. 1385 0. 0000 0. 0331 0. 1131 
APPENDIX TABLE 3- Total Body Weight and Selected Organ Weights (Gm. ) of 29 Day Control Rabbit 
Fetuses Showing Ratio Wet Heart/Kidney Wt . , Mean and Standard Error 
fue C#J Body Heart Heart Ratio 
fetus no. wt. wet dry Liver Kidney lung wet heart/kidney wt . 
-
1 53 . 9 0 . 2978 o .  0381 4. 0993 0 . 2702 0 . 6687 1 . 1021 
2 56 . 7  0 . 3504 0 . 0411 5 . 0152 0 . 2565 0 . 5767 1 . :3660 
3 42 . 4  0 . 2499 0 . 0285 3 . 0411 0 . 1882 0 . 3670 1 . 3278 
4 55 . 2  0 . 2749 0 . 0355 3 . 5994 0 . 2818 0 . 5352 0 . 9755 
5 66. 3 0 . 376.5 0 . 0502 5 . 5132 0 . 3169 0 . 7524 1 . 1880 
6 55 . 3  0 . 3052 0 . 0384 4 . 1443 0 . 3480 0 . 5266 0 . 8770 
7 56 . 9  0 . 2916 O .  OJ81 4. 3487 0 . 2767 0 . 5900 1 . 0538 
8 5.5 . 8  0 . 3177 o .  0386  5 .  3897 0 . 2832 0 . 6277 1 . 1218 
9 61. 7  0 . 3942 O .  Ol'-87 4 . 2L1.73 0 . 3214 0 . 6339 1 . 2265 
Mean 56. 0 0 . 3175 0 . 0396 4 . 3775 0 . 2825 o . _5864 1 . 1376 
S .  E. 2 . 1  0 . 0141 0 . 0000 0 . 2701 0 . 0141 0 . 0346 0 . 0519 
APPENDIX TABLE 4- Total Body Weight and Selected Organ Weights (Gm. ) of 29 Iay Control Rabbit 
Fetuses Showin g Ratio Wet Heart/Kidney Wt. , Mean and Standard Error 
llie Gi/=4 Body Heart Heart Ratio 
fetus no . wt . wet dry Liver Kidney Illng wet heart/kidney wt . 
1 55 .8 0. 4262 o .  0568 4. 78.58 0. 2967 0.4796 1. 4364 
2 53. 2  0. 2676 0 . 0377 5. 0497 0. 2833 0.4992 0. 9445 
3 51 . 3  0. 2682 0 . 0370 5. 1455 0. 2880 0. 5373 0 . 9312 
4 39. 0 0. 2589 0 . 0306 2 . 7091 0. 1891 o . 4041 1 . 3691 
5 40. 4  0. 2481 0. 0307 3 . 0022 0 . 1902 0. 4-402 1 . 3044 
6 46. 3 0. 2327 0. 0312 3 - 5871 0 . 2221 0. 6164 1.0477 
7 55. 6 0 . 3289 0. 04l-1,7 5. 3329 0. 2825 0. 6022 1. 1642 
Mean 48 .8 0. 2900 0. 0383  4. 2303 0 . 2502 0. 5112 1.1710 
S . E. 2 . 6  0.0244 0. 0000 0 . 4159 0. 0173 0. 0282 0. 0768 
0) 
-...:, 
APPENDIX TABLE 5- Total P.ody Weight and Selected Organ Weights (Gm. ) of 29 Cay Control Rabbit 
Fetuses Showing Ratio Wet Heart/Kidney Wt. , Mean and Standard Error 
Doe C#5 Body Heart Heart- Ratio 
fetus no. wt. wet dry Liver Kidney Illng wet heart/kidney wt . 
1 36 . 5  0 . 2024 0. 0288 2. 3769 0 . 1502 o . 4362 1. 3475 
2 46 . 5  0 . 2485 0 . 0322 3. 1635 0 . 1916 o . 6879 1 . 2969 
3 41 . 9  0 . 1893 0. 0249 2 . 7154 0 . 1937 o. 5891 0 . 9772 
4 52. 1 0. 2559 0. 0340 4. 0280 0 . 2395 0. 6536 1 . 0684 
5 46. 7 0. 2097 0. 0277 3. ?133 0. 1953 0. 6157 1. 0737 
6 55 . 4  0 . 2648 0. 0369 4 . 2674 0 . 2397 0. 7400 1 . 1047 
Mean 46. 5 0. 2284 0. 0307 3. 2939 0. 2016 0 . 6204 1. 1447 
S . E. 2 98 0 .. 0100 0. 0000 0. 2989 0. 0100 0. 0424 0. 0583 
ex, 
CX> 
APPENDIX TABLE 6- Total Body Weight and Selected Organ Weights (Cm. ) of 29 lliy Control &bbit 
Fetuses Showing Ratio Wet Heart/Kidney Wt . , Mean and Standard Error 
Doe C#6 P.ody Heart Heart Ratio 
fetus no . wt. wet dry Liver Kidney lung wet heart/kidney wt . 
1 33.7 0. 2115 0. 0215 1. 9934 0. 138 5 0. 5981 1. 5270 
2 33.1 0. 1938 0. 0226 2. 3427 0. 1352 o. 5041.} 1.4334 
J 33. 6  0. 1731 0. 0199 2. 4773 0. 1362 0. 5701 1. 2709 
4 37. 2 0. 1816 0. 0208 2 .8768 0. 1321-1- 0. 6360 1.3716 
5 28. 2 0. 1526 0. 0171 2. 1054 0. 1140 0.4677 1.3385  
6 29. 7 0.1611 0. 0180 2. 0397 0. 1332 o. 4705 1. 2094 
7 39.8 0. 1823 0. 0231 3. 2709 0. 1428 o. 6816 1. 2766 
8 J8. l 0. 1735 0. 0200 2. 9506 0. 1537 0. 5044 1. 1288 
9 27.4  0. 1743 0. 0188 1.8718 0. 0920 0.4177 1.8945 
Mean 33. 4  0. 1782 0. 0202 2. 436.5 0. 1J08 0. 5389 1.3834 
S . E. 1. 5 0. 0000 0 . 0000 0. 1643 0. 0000 0 . 0282 0. 0748 
APPENDIX TABLE 7- Total Body Weight and Selected Organ Weights (Gn. ) of 29 Day Control Rabbit 
Fetuses Showing Ratio Wet Heart/Kidney Wt. ,  Mean and Standard Error 
Ike C#-7 Pody Heart Heart Ratio 
fetus no . wt. wet dry Liver Kidney Inng wet hear/ kidney wt. 
1 27 . 8  0 . 1234 0 . 0167 1 . 2723 0 . 1067 0 . 3633 1 . 1565 
2 37 . 4  0 . 1334 0 . 0197 2 . 1490 0 . 1294 o . 4845 1 . 0309 
J 35 . 5  0 . 1548 0 . 0236 2 . 0374 0 . 1157 0 . 6117 1 . 3379 
4 33 . 7  0 . 1279 0 . 0196 1 . 5905 0 . 1284 o . 4673 0 . 9961 
5 34 . 2  0 . 1131 0 . 0155 1 . 6006 0 . 1237 o . 4352 0 . 9143 
6 34. 2  0 . 1061 0 . 0152 1 . 5255 0 . 1194 0 . 5483 0 .8886 
Mean 33 .8  0 . 1264 o .  0183 1 . 6958 0 . 1205 o . 4850 1 . 0540 
S .  E. 1. 3 0 . 0000 0 . 0000 0 . 1352 0 . 0000 0 . 0346 0 . 0685  
'° 
0 
APPENDIX TABLE 8- Total P.ody Weight and Selected Organ Weights (Gn. ) of 29 Day Control Rabbit 
Fetuses Showing Ratio Wet Heart/Kidney Wt. , Mean and Standard Error 
Doe C#8 Body Heart Heart Ratio 
fetus no. wt. wet dry Liver Kidney lll;ng wet heart/kidney wt. 
1 45.8 0. 1951 0.0321 2 .0011 0. 1527 0. 57 56 1. 2776 
2 46. o 0. 1646 0.0252 2. 1842 0. 1663 0.4503 0. 9897 
J 54. 9 0 . 20¼8 0. 0343 J. 4024 0 . 2274 0. 6019 0. 9006 
4 J8.8  0. 11(34 0 .0229 1. 9790 0. 1458 o .4464 0. 9835 
5 32 . 2  0. 1878 0. 0313 1.5771 0 . 1194 0 . 3517 1. 5728 
6 35 . 4  0 . 1477 0.0235 1. 5999 0. 1214 0.4578 1. 2166 
Mean 4-2 . 2  0 . 1739 0 .0282 2. 1239 0. 1555 o. 4806 1. 156s 
S. E. J.4 0.0000 0.0000 0. 2736 0 . 0141 0. 0374 0. 1019 
'° 
t-' 
APPENDIX TABLE 9- Total Body Weight and Selected Organ Weights (On. ) of 29 Day Experimental I 
Rabbit Fetuses Showing Ratio Wet Heart/Kidney Wt. , Mean and Standard Error 
Doe ExI#l Body Heart Heart Ratio 
fetus no. wt. wet dry Liver Kidney Illng wet heart/kidney wt. 
1 58. 5 0. 3814 0. 0454 5. 0689 0. 2590 1. 0079 1. 4725 
2 56.8 0. 2954 0. 0370 4. 9782 0. 2745 0.9152 1 . 0761 
Mean 57. 7 0. 3384 0. 0412 5. 0235 0. 2667 0.9615 1. 2743 
S . E . 0.84 0. 0424 0. 0000 0. 0435 0. 0000 0. 0447 0. 1979 
APPENDIX TABLE 10- Total Body Weight and Selected Organ Weights (Gn. ) of 29 03.y Experimental I 
Rabbit Fetuses Showin g Ratio Wet Heart/Kidney Wt • •  Mean and Standard Error 
Doe Ex.I#2 Body Heart Heart Ratio 
fetus no. wt. wet dry Liver Kidney lllng wet heart/kidney wt . 
1 38.4 0. 2288 0. 0303 3. 2816 0 . 1833 0 . 3739 1. 2482 
2 49. 2 0 . 2949 0 . 0374 4. 4924 0 . 2584 0. 6239 1. 1412 
3 46. 2 0 . 3543 0 . 0447 4 . 2286 0. 2727 o . 4168 1 . 2992 
4 41. 7 0 . 2386 O . OJOO 4. 1881 0 . 2313 0. 3768 1 . 0315 
5 45 . 5  0. 2975 0 . 0384 4. 5458 0. 2346 o . 4681 1 . 2681 
Mean 44. 2 0. 2828 0. 0361 4. 1473 0. 2360 o . 4519 1 . 1976 
S . E .  1 . 9  0 . 0223 0 . 0000 0 . 2273 0 . 0100 0. 0458 0 . 0489 
APPENDIX TABLE 11- Total E-0dy Weight and Selected Organ Weights (Gm. ) of 29 Day Experimental I 
Rabbit Fetuses Showing Ratio Wet Heart/Kidney Wt. , Mean and Standard Error  
Do e  ExI#J Body Heart Heart Ratio 
fetus no. wt. wet dry Liver Kidney lung wet heart/kidney wt. 
1 50. 4 0. 3052 0. 0375 3. 6126 0. 2120 0. 8101 1.4396 
2 52. 7 0. 3017 0. 0368 3. 7781 0. 2083  0. 8045 1. 4483 
3 36. 7 0. 2200 0 .. 0262 2. 6921 0. 1641 o. 6415 1. 3406 
4 52.2 0. 3081 o. 0381 3.8764 0. 2367 0. 5413 1. 3016 
5 44.4 0. 2 537 0. 0332 3 .2814 0. 1756 0. 6863 l. Lwl+7 
6 46 .8  0.2891 0. 0352 3. 6832 0. 1950 0. 6234 1. 4825 
7 52 . 2  0. 28 51.} 0. 038 5 4. 9109 ().2488 0. 5962 1 . 1471 
8 45.2 0 .2423 0. 0321 3.8863 0. 1835 0. _5822 1. 3204 
9 52. 9 0.2594 0. 0372 4. 3648 0.2190 0. 5572 1. 1844 
Mean 48. 2 0 . 2738 0. 0349 3. 7873 0.2047 0. 6491 1. 3454 
S. E.  1.8 0. 0100 0. 0000 0.2076 0. 0000 0. 0316 0. 0400 
� 
APPENDIX TABLE 12- Total Body Weight and Selected Organ Weights (Gm. ) of 29 Iay Experimental I 
Rabbit Fetuses Showing Ratio Wet Heart/Kidney Wt. , Mean and Standard Error 
Doe ExI#4 Body Heart Heart Ratio 
fetus no . wt. wet dry Liver Kidney lung wet heart/kidney wt . 
1 41. 4  0 . 2393 0 . 0311 2 . 8402 0 . 1599 0 . 7043 1 .4965 
2 45 . 6  0 . 2536 0 . 0280 3 . 3098 0 . 1793 0 . 6111 1 . 4143 
J 44. 1 0 . 2437 0 . 0282 3 . 0116 0 . 1755 0 . 6265 1 . 3886 
4 36 . 3 0 . 2318 0 . 0277 2 . 7612 0. l3L1,8 o . 4937 1 . 7195 
5 56 . 0  0 . 2358 0 . 0322 4 . 1941 0 . 2377 0 . 6519 0 . 9920 
6 49 . 6  0 . 2581 0 . 0303 3 . 6639 0 . 1986 o. 7486 1 . 2995 
Mean 45 . 5 0 . 2437 0 . 0295 3 . 2968 0 . 1809 0 . 6393 1 . 3850 
S. E. 2 .8 0 . 0000 0 . 0000 0 . 2247 0 . 0100 0 . 0346 0 . 0974 
'° "' 
APPENDIX TABLE lJ- Total Body Weight and Selected Organ Weights (Gm. ) of 29 Day Experimental I 
Rabbit Fetuses Showing Ratio Wet Heart/Kidney Wt. ,  Mean and Standard Error 
Doe "ExI#5 Body Heart Heart Ratio 
fetus no. wt. wet dry Liver Kidney lllng wet heart/kidney wt . 
1 50 . 8  0 . 2308 0. 0253 4.4319 0. 1889 o. 7978 1. 2218 
2 55. 0 0 . 3407 0. 0380 4 . 9817 0 . 2159 0 .9032 1. 5780  
3 50. 3 0. 2624 0. 0301 4 . 5003 0. 1888 o . 6675 1 . 3898 
4 57 . 2 0 . 3054 0 . 0371 5 . 2119 0. 2175 0 . 8787 1. 4041 
Mean 53 . 3  0 . 2848 0. 0326 4. 7814 0. 2027 0. 8118 1 . 3984 
S . E. 1 . 7 0. 0223 0 . 0000 0. 1884 0. 0000 0. 0519 0. 0721 
'° °' 
APPENDIX TABIE 14- Total Body Weight and Selected Organ Weights (Gn. ) of 29 Day Experimental I 
Rabbit Fetuses Showing Ratio Wet Heart/Kidney Wt. , Mean and Standard Error 
Doe ExI#=6 Eody Heart Hear:t Ratio 
fetus no. wt. wet dry Liver Kidney Inng wet heart/kidney wt. 
1 53. 3 0.2205 O . OJ82 J. 1294 0 . 2182 o .  5810 1.0105 
2 53.8 0 .2491 0.0448 J.6652 0. 1774 0. 5674 1.4041 
Mean 53 . 6 0.2348 0.0415 3 . 3973 0. 1978 o .  57q,2 1. 2073 
S . E. 0.2 0. 0141 0. 0000 0.2677 0. 0173 0.0000 0.1964 
'° � 
APPENDIX TABLE 15- Total Body Weight and Selected Organ Weights (Gm.) of 29 Day Experimental I 
Rabbit Fetuses Showing &tio Wet Heart/Kidney Wt. , Mean and Standard Error 
Doe ExI#7 Body Rea.rt Heart Ratio 
fetus no. wt. wet dry Liver Kidney IJ.mg wet heart/kidney wt. 
1 39.8  0. 1509 0. 0242 2. 1502 0. 1037 0. 3373 1.4551 
2 47. 0 0. 1832 0. 0102 2 . 6070 0. 1592 o.4904 1. 1507 
3 47.4 0. 1741 0. 0278 2. 6618 0. 1451 0. 4130 1. 1998 
4 43. 7 0. 1603 0. 0265 2. 3613 0. 1308 o.4285 1. 2255 
5 40 . 5  0. 18 57 0. 0296 2 . 1326 0. 1195 0. 3783 1. 5539 
6 38. 2 0. 1566 0. 0257 1. 8392 0. 0916 0. 3552 1. 7096 
7 56.8  0. 2371 0. 0426 3. 6912 0. 1863 0. 5632 1. 2726 
8 43. 3 0. 1980 0. 0319 2. 3814 0. 1347 o.4548 1. 4699 
9 36 . J 0. 1363 0. 0228 2. 1486 0. 1272 0. 4,297 1. 0715 
Mean 43. 7 0. 1785 0. 0290 2. 4414 0. 1331 0 . 4278 1. 3454 
S. E. 2 .. 1 0. 0000 0. 0000 0. 1777 0. 0000 0. 0223 0. 0700 
� 
APPENDIX TABLE 16- Total Body Weight and Selected Organ Weights (Gm. )  of 29 Da,y Experimental I 
&.bbit Fetuses Showing Ratio Wet Heart/Kidney Wt . , Mean and Standard Error 
Doe 'ExI#8 13ody Heart Heart Ratio 
fetus no. wt . wet dry Liver Kidney 1llng wet heart/kidney wt .  
1 56. 1 0 . 2ll�2 0 . 0378 3 . 1539 0. 1851 0 . 5713 1 . 1572 
2 56 . 6  0 . 1730 0 . 0307 3 . 4657 0 . 2093 0 . 6135 0 .8265 
3 47 . l  0 . 1879 0 . 0327 2 . 3442 0. 1811 o. 3817 1. 0375 
4 61. 5 0. 2414 0 . 0465 3 . 5333 0 . 2025 0 . 5541 1 . 1920 
5 26. 6  0 . 1106 0 . 0160 0 . 9752 0 . 0834 0 . 2760 1. 3261 
6 35 . 7  0 . 1295 0 . 0210 1.8218 0 . 1191 0 . 3652 1 . 0873 
7 57 . 6  0 . 2 508 0. 0455 3 . 0207 0 . 1812 0 . 5784 1 . 3841 
Mean 48 . 7  0 . 1867 0 . 0328 2 . 6164 0 . 1659 o .4771 1 . 1443 
s .  E. 4. 9 0 . 0173 0 . 0000 0. 3588 0 . 0141 0 . 0489 0 . 0700 
. APPENDIX TABLE 17- Total Body Weight and Selected Organ Weights (Gm. ) of 29 Day Experimental I 
Rabbit Fetuses Showing Ra.tic Wet Heart/Kidney Wt . ,  Mean and Standard Erro r  
Doe ExI#9 Eody Heart Heart Ratio 
fetus n.o ., wt. wet dry Liver Kidney lung wet heart/kidney wt . 
1 55.8  0. 3338 0. 0444 5.8253 0. 2795 0.8255 1. 1942 
2 31. 0 0 . 1800 0 . 0219 2. 2937 0 . 1388 0 . 3568 1. 2968 
3 57 . 6  0. 3316 0. 0424 5 . 8452 0 . 2476 0. 7566 1. 3392 
4 49 . 9 0. 2604 0. 0345 5 . 2698 0. 2241 0. 5985 1. 1619 
Mean 48 . 6  0 .2764 0. 0358 4 . 808 5  0. 2225 0 . 6343 1. 2480 




APPENDIX TABLE 18- Total Body Weight and Selected Organ Wei?hts (Gm. )  of 29 Day Experimental II 
Rabbit Fetuses Showing Ratio Wet Heart/Kidney Wt. , Mean and Standard Error 
Doe Ex II#=l Body Heart Heart Ratio 
fetus no . wt. wet d ry  Liver Kidney Illng wet heart/kidney wt. 
1 46 . o  0 . 2822 0. 0492 2. 7764 0 . 1848 0. 3747 1.5270 
2 36 . 7  0. 2052 0. 0389 1 . 9498 0 . 1522 0 . 3689 1 . 3482 
3 30. 2  0. 2028 0. 0323 1. 5866 0. 1218 0. 3128 l . 6650 
4 42 . 9  0 . 2636 0 . 0443 2. 9066 0. 1920 0. 5266 1.3729 
5 53. 4  0. 2953 0. 0540 3.7106 0 . 2136 0. 5401 1 . 3824 
6 50.1 0. 2900 0. 0513 J. 528 5 0. 2247 0. 4834 1. 2906 
7 53 . 6  0. 3098 0. 0562 3 - 5989  0. 2248 0. 5434 1. 3781 
Mean 44. 7  0 . 2641 0. 0466 2 . 8653 0. 1877 0 . 4499 1 . 4234 
S . E. 3. 3 0. 0141 0. 0000 0. 3151 0. 0100 0. 0346 0 . 0479 
..... 
0 ..... 
APPENDIX TABLE 19- Total Body Wei�ht and Selected Or�an Weights (Gn. ) of 29 Day Experimental II 
Rabbit Fetuses Showing Ratio Wet Heart /Kidney Wt., Mean and Standard Error 
Doe ExII#2 Body Heart Heart Ratio 
fetus no. wt. wet dry Liver Kidney lung wet heart/kidney wt. 
1 48. 6 0. 2385 0. 0413 2 . 3173 0. 1586 o. 6645 1 .. 5037 
2 49. 0 0 . 1916 0 . 0326 2 . 9760 0 . 1805 0 . 6001 1. 0614 
3 47 . 8  0. 2500 0 . 0425 2 . 0141 0. 1570 0. 5926 1. 5923 
4 40. 2 0 . 2050 0. 0341 2 . 0903 0. 1558 0 . 3645 1. 3157 
5 46.8 0. 2759 0 . 0431 3 . 18 _58 0. 1772 0 . 5468 1. 5569 
6 52 . 5  0. 2782 0 . 0484 J. OJ40 0. 1885 0 . 5634 1 . 4758 
Mean 47 . 5  0 . 2398 0. 0403 2. 6029 0 . 1696 0 . 5553 1. 4176 




APPENDIX TABLE 20- Total Body Weight and Selected Organ Weights (Gm . ) of 29 Day Experimental II 
Rabbit Fetuses Showing Ratio Wet Heart/Kidney Wt. , Mean and Standard Error 
Doe ExII#=3 I3ody Heart Heart Ratio 
fetus no . wt. wet dry Liver Kidney Illng wet heart/kidney wt . 
1 39.4 0 . 1182 0. 0172 l . _5977 0 . 1233 0 . 4914 o. 9586  
2 31. 4  0 . 1051 0 . 0161 1 . 2348 0 . 0878 0. 3830 1 . 1970 
J 40 . 1  0 . 1371 0. 0205 1.841+6 0. 1373 0 . 5926 o. 9985 
4 36. 7 0 . 1159 0. 0184 1 .8378 0. 1219 0 . 4363 0. 9507 
5 39 . 2  0. 1324 0. 0211 2 . 2716 0. 1301 o. 4645 1 . 0176 
6 37 . 5  0. 1282 0. 0204 1 . 8993 0 . 1246 o. 4192 1. 0288 
7 44. 2 0. 1389 0 . 0201 2. 2896 0 . 1498 0 . 5140 0 . 9272 
8 39. 1 0 . 1421 0 . 0211 1. 9768 0 . 1470 0. 5694 0 . 9666 
9 34. 2  0. 1335 0 . 0229 1 . 6714 0. 1240 0. 3744 1 . 0766 
Mean J8. 0 0. 1279 0 . 0197 1. 8470 0. 1273 o. 4716 1 . 0135 
S . E. 1 . 2  . 0. 0000 0. 0000 0. 1090 0 . 0000 0 . 0244 0. 0264 
APPENDIX TABLE 21- Total Body Weight and Selected Organ Weights (Gm. ) of 29 Day Experimental II 
Rabbit Fetuses Showing R8.tio Wet Heart/Kidney Wt. , Mean and Standard Error 
Doe ExII#4 Ibdy Heart Heart &tio 
fetus no . wt. wet dry Liver Kidney lung wet heart/kidney wt. 
1 58 . 2  0. 3631 0. 0577 3. 7127 0. 2673 0. 8234  1 . 3 .583 
2 53. 9  0 . 2668 0. 0415 3. 8152 0. 2278 0. 6034 1 . 1712 
) 56 . 2  0. 2863 0. 0500 3 .4500 0. 1985 0. 6007 1 . 4423 
4 57 . 0  0. 2946 0. 0469 3. 4337 0 . 1927 0 • .5948 1 • .5288 
5 51 . 5 0. 3183  0. 0530 3 . 1901 0 . 2131 0 . 7118 1. 4936 
Mean 55 . 4  0 . 3058 0. 0498 3. 5203 0 . 2198 o. 6668 1. 3988 
S . E. 1. 2 0. 0141 0. 0000 0. 1104 0. 0100 0. 0435 0. 0632 
APPENDIX TABLE 22- Total Body Weight and Selected Organ Weights (Gm. ) of 29 Day Experimental II 
Rabbit Fetuses Showing Ratio Wet Heart/Kidney Wt. ,  Mean and Standard Error 
Doe ExII#=5 Eody Heart Heart Ratio 
fetus no. wt. wet dry Liver Kidney Illng wet heart/kidney wt. 
1 48 .8 0. 1774 0 . 0286 2 . 5386 0 . 1637 0 . 5599 1 . 0836 
2 53 . 2  0 . 2059 0. 0363 3. 0252 0 . 1522 0. 5526 1 . 3528 
':I 47 . 4  0 . 1912 0. 0279 2 . 5629 0 . 1719 o. 4706 1 . 1122 / 
4 42. 1 0 . 1553 0 . 0228 1 . 9684 0 . 1326 0.4804 1 . 1711 
5 32 . 0  0 . 1173 0. 018 5 1 . 2856 0. 0936 0 . 3291 1 . 2532 
6 40. 7 0 . 1629 0. 0249 2 .2873 0 . 1273 o . 4193 1 .2796 
7 48. 0 0 . 1901 0. 0319 2.8186 0 . 1292 o .4110 1 . 4713 
8 45 . 5  0. 1700 0. 0285 2 . 5453 0. 1436 o . 4869 1 . 18 38 
9 40. 2 0 . 1551 0. 0248 2 . 1978 0 . 1237 o. 4485 1. 2538 
10 44. 0 0 . 1715 0 . 0294 2 . _5860 0. 1459 0 • .5419 1 . 1754 
Mean 44.2 0 . 1696 0. 0273 2. J815 0 . 1383 0. 4700 1. 2336 
S. E. 1. 9 0 . 0000 0 . 0000 0. 1_542 0 . 0000 0 . 0223 0 . 0360 
'I P. 
., . 
APPENDIX TABLE 23- Total Body Weight and Selected Organ Weights (Gn. ) of 29 Day Ex:pe rimental II 
Rabbit Fetuses Showing Ratio Wet Heart/Kidney Wt. , Mean and Standard Error 
toe ExII#6 Body Heart Heart Ratio 
fetus no. wt . wet dry Liver Kidney Illng wet heart/kidney wt. 
1 44.9 0. 2061 0. 0338 2 • .5403 0. 1718 0.3825 1 . 1996 
2 57 . 3 0 . 2246 0 . 0401 3 . 5135 0 . 2057 o . 4035 1. 0918 
3 56. 0  0. 2372 0 . 04-23 3. 3089 0. 2070 0. 4980 1 . 1458 
4 59. 2  0 . 2653 0. 0447 3. 4708 0. 2005 0. 4722 1. 3231 
5 43.7 0. 2084 0. 0354 1 . 9579 0. 1701 0. 3634 1. 2251 
6 47.2  0. 2082 0. 0369 2. 3608 0 . 1536  0. 3323 1. 3554 
7 48. 0 0. 2083 0 . 0364 2. 3164 0. 1581 0. 3468 1 . 3175 
8 39. 2 0. 1742 0. 0306 1.8638 0 . 0981 0. 2520 L 7757 
9 45. 4 0 . 1766 0 . 0299 2. 3015 0. 1712 0.2597 1. 0315 
Mean 49. 0 0. 2121 0. 0366 2. 6259 0. 1706 0. 3678 1. 2739 
S .  E. 2 . 3  0 . 0000 0. 0000 0.2130 0 . 0100 0. 0264 0. 0721 
...., 
0 
APPENDIX TABLE 24- Total Pody Weight and Selected Organ Weights (Gm. )  of 29 Day Experimental II 
Rabbit Fetuses  Showin g Ratio Wet Heart/Kidney Wt. , Mean and Stan dard Error 
Doe ExII#=7 Body Heart Heart Ratio 
fetus no. wt. wet dry Liver Kidney lung wet heart/kidney wt. 
1 31. 9  0. 1227 0.0189 1.8124 0.0923 0. 3347 1. 3293 
2 31.4 0.1074 0. 0167 1. 4934 0. 0994 0.3382 1.0804 
J 33.9 0.1171 0.0181  1. 6963 0.1072 0. 3177 1.0923 
4 J2.8 0. 1156 0.0193 1.5179 0.0897 0. 4088 1. 2887 
5 37.9 0 . 1406 0 . 0218 1.9912 0 . 1217 0.4367 1.1552 
6 32. 9 0.1280 0.0192 1.6642 0.1122 0.3870 1.1408 
7 34.4 0.1065 0. 0179 1.8132 0.1043 0.4549 1.0210 
8 34.9 0.1275 0.0203 1. 7818 0.1277 0.3349 0. 9984 
Mean 33.8  0.1206 0.0190 1. 7213 0.1068 0.3766 1. 1382 
S . E .  9. 7 0. 0000 0.0000 0.0574 0. 0000 0.0173 0. 0412 
ti 
APPENDIX TABLE 25- Selected Organ Weights of 29 Day Control Rabbit Fetuses Expressed as 
i of Total Pody Weight 
Doe C#l Pody Heart Heart 
fetus no . wt . (Gm. ) wet (%) dry (%) Liver (%) Kidney (%) Inng (%) 
l 46 . 2  0 . 51 0 . 06 6 . 87 0 . 47 1 . 45 
2 38 . 6 0 . 63 0 . 06 6 . 62 0 .45 1 . 34 
J /4-6 . 1  0 . 56 0 . 06 6 . 84 0 . 40 1 . 21 
4 46 . 9 o . 49 0 . 06 8 . 29 o . 41 0 . 94 
5 44. J 0 . 51 0 . 06 8 . 41 o . 43 1 . 11 
6 45 . 2  0 . 56 0 . 06 8 . 64  0 . 37 1 . 50 
7 37 . 4 . o .45 0 . 05 7 . 07 0 . 35 0 . 98 
8 :n . 1  o . 49 0 . 06 7 . 42 0 . 33 1 . 14 
Mean 42 . 7  0 . 53 0 . 06 7 . 52 0 . 40 1 . 21 
S. E. 1 . 5 0 . 02 o . oo 0 . 28 0 . 01 0 . 07 
� 
APPENDIX TABLE 26- Selected Organ Weights of 29 Day Control Rabbit Fetuses E>cpressed as 
% of Total Body Weight 
Doe C#=2 Eody Heart Heart 
fetus no. wt. (Gm. )  wet (%) dry (%) Liver (i) Kidney (%) Lung (%) 
-
1 42 . J  o . 46 0 . 05 7 . 04 o . 42 1 . 65 
2 J6 e 2  o . 46 0 . 05 7 . 83 0 . 47 2 . 06 
3 35 . 6 0 . 54 0 . 05 6 . 41 0 . 40 1 . 57 
4 38 . 5 o .47 0 . 04 6 . 33 0 . 37 1 . 49 
5 37 . 4 o . 49 0 . 05 7 . 70 o . 42 1 . 77 
6 33 . 2  0 . 63 0 . 06 6 . 58 0 . 35 1.61 
Mean 37 . 2  0 . 51 0 . 05 6 . 98 o.41 1 . 69 
S. E. l . J 0 . 03 o . oo 0 . 27 0 . 01 0 . 08 
APPENDIX TABLE 27- Selected Organ Weights of 29 Day Control Rabbit Fetuses Expressed as 
% of Total Body Weight 
Doe C#3 P.ody Heart Heart 
fetus no s wt . (Gm. ) wet (%) dry (%) Liver (%) Kidney (%) Illng (%) 
1 53 . 9  0 . 55 0 . 07 7 . 60 0 . 50 1 . 24 
2 56 . 7  0 . 61 0 . 07 8 .8L� 0 . 45 1. 01 
3 42 . 4  0 . 58 0 . 06 7 . 17 o .44 0 .86 
4 55 . 2 o . 49 0 . 06 6 . 52 0 . 51 0 . 96 
5 66. 3 0 . 56 0.07 8 . 31 o . 47 1 . 13 
6 .5.5 . 3 0 . 55 0 . 06 7 . 49 0 . 62 0 . 95 
7 .56 . 9  0 . 51 0 . 06 7 . 64 0.48 1. 03 
8 55 .8 0 . 56 0 . 06 9.65 0 . 50 1 . 12 
9 61 . 7  0 . 63 0 . 07 6 . 88 0 . 52 1. 02 
Mean 56 . 0  0 . 56 0 . 06 7 . 79 o.49 1 . 04 
S. E. 2 . 1  0 . 01 o.oo 0 . 33 0 . 01 0 . 04 
...., ...., 
APPENDIX TABLE 28- Selected Organ Weights of 29 Day Control Rabbit Fetuses Expressed as 
% of Total Body Weight 
Doe C#4 Pody Heart Heart 
fetus no . wt . (Gn. ) wet (%) d�J (%) Liver (%) Kidney (%) Illng (%) 
1 55 .8  0 . 76 0 . 10 8 . 57 0 . 53 0 . 85  
2 53 . 2  0 . 50 0 . 07 9 . 49 0 . 53 0 . 93 
3 51 . 3 0 . 52 0 . 07 10 . 03 0 . 56 1 . 04 
4 39 . 0  o . 66 0 . 07 6 . 94 0 . 48  1 . 03 
5 40 .4  0 . 61 0 . 07 7 . 43 o . 47 1 . 08 
6 46 . J  0. 50 0 . 06 7 . 74 o . 47 1 . 33 
7 55 . 6  0 . 59 0 . 08 9 . 59 0 . 50 1 . 08 
Mean 4B .8 0.59 0 . 07 8 . 54 0 . 50 1 . 04 
S .  E. 2 . 6  0 . 04 o . oo o . 45 0 . 01 0 . 0.5 
APPENDIX TABLE 29- Selected Organ Weights of 29 Day Control Rabbit Fetuses Expressed as 
% of Total Body Weight 
Doe C#5 fudy Heart Heart 
fetus no. wt. (Gn. )  wet (%) dry (%) Liver (%) Kidney (%) Lung (%) 
1 36.5 0.55 0.07 6.51 o.41 1.19 
2 46.5 0.53 0.06 6 . 80 o . 41 1 . 47 
3 41 . 9  0.45 0 . 05 6.48 o.46 1 . 40 
4 52 . 1  o . 49 0.06 7.73 o . 45 1.25 
5 46 . 7  O . ll-4 0 . 05 6 . 87 0 . 41 1 . 31 
6 55 . 4  0.47 0 . 06 7 . 70 o . 43 1.33 
Mean 46 . 5 0 .48 0 . 05 7.01 o.42 1.32 
S.E. 2 . 7  0 . 01 o . oo 0 . 23 o . oo 0.04 
...., ...., 
APPENDIX TABLE 30- Selected Organ Weights of 29 Day Control Rabbit Fetuses E,cpressed as 
% of Total Body Weight 
Doe C#6 B:>dy Heart Heart 
fetus no . wt . (Gm. ) wet (%) dry (%) Liver (%) Kidney (%) lllng ('fo) 
-
1 33 . 7 0.62 0 . 06 5 . 91 o . 41 1 . 77 
2 33 . 1  0 . 58 0 . 06 7 . 07 o.4o 1 . 52 
3 33 . 6  0 . 51 0.05 7.37 o.4o 1.69 
4 37 . 2  0 . 48  0.05 7 . 73 0 . 35 1 . 70 
5 28 . 2  0 . 54 0 . 06 7.46 0 . 40 1 . 65 
6 29 . 7 0 . 54 0 . 06 6 .86  o.44 1.58 
7 39 .8  o . 45 0.05 8 . 21 0 . 35 1 . 71 
8 J8 . l  0 . 45 0 . 05 7 . 74 o . 4o 1 . 32 
9 27 .4  0 . 63 0 . 06 6 . 83  0. 33 1. 52 
Mean 33 . 4  0 . 53 0 . 05 7 . 24 0 . 38 1 . 60 
S . E . 1.4 0 . 02 o . oo 0 . 22 0.01 0 . 04 
...., ...., 
APPENDIX TABLE Jl- Selected Organ Weights of 29 Day Control Rabbit Fetuses  Expressed as 
% of Total Body Weight 
Doe C·/f7 P.ody Heart Heart 
fetu s  no. wt. (Gm. ) wet (%) dry (%) Liver (i) Kidney (%) Illng (%) 
-
1 27 .8  o .44  0 . 06 4. 57 0 . 38 1 . 30 
2 37 . 4  0 . 35 0 . 05 5 . 74 0 . 34 1 . 29 
J 3.5 • .5 0 . 4J 0 . 06 .5 . 73 0 . 32 1 . 72 
4 33 . 7  0 . 37 0 . 05 4 . 71 0 . 38 1 . 38 
5 34 . 2  0 . 33 0 . 04 4 . 68 0 . 36 1 . 27 
6 34 . 2  0 . 31 0 . 04 4. 46 0 . 34 1 . 60 
Mean 33 .8  0 . 37 0 . 05 4 . 98 0 . 35 1 .43 
S. E. 1 . 3  0 . 02 o . oo 0 . 24 o . oo 0 . 08 
APPENDIX TABLE 32- Selected Organ Weights of 29 Day Control Rabbit Fetuses  Expressed as 
% of Total Body Weight 
Doe C-#8 P.ody Heart Heart 
fetus no . wt . (Gm. ) wet (%) dry (%) Liver (%) Kidney (%) Inng (%) 
1 45.8 o . 42 0 . 07 4 . J6 O . JJ 1.25 
2 46 . 0 0.35 0 . 05 4 . 74 0 . 36 0 . 97 
3 54. 9  0.37 0 . 06 6 . 19 o . 41 1 . 09 
4 38 .8 0.36 0 . 05 5.10 0.37 1 . 15 
5 32 . 2  0 . 58 0 . 09 4 . 89 0 . 37 1.09 
6 35 . 4  o . 41 0 . 06 4 . 51 0 . 34 1 . 29 
Mean 42 . 2  0 . 42 0 . 06 4 . 97 0 . 36 1 . 14 
S. E. 3 . 4  0 . 03 o . oo 0 . 27 0 . 01 0.05 
APPENDIX TABLE 33- Selected Organ Weights of 29 Day Experimental I Rabbit Fetuses Expressed 
as % of Total Body Weight 
Doe ExI#=l Body Heart Heart 
fetus no. wt . (Gm. ) wet (%) d ry (%) Liver (%) Kidney (%)  :Umg (%)  
1 58 . 5  0 . 65 0 . 07 8 . 66 0 .44 1. 72 
2 56 .8  0 . 52 0 . 06 8 . 76 o .48 1 . 61 
Mean 57 . 7  0 . 58 0 . 06 8 . 71 0 . 46 1 . 66 
S .  E. 0 .8 0 . 06 o . oo 0 . 04 0 . 01 0 . 05 
...., ...., 
APPENDIX TABLE 34- Selected Organ Weights of 29 Day Experimental I Rabbit Fetuses E,cpressed 
as % of Total Body Weight 
llie ExI#2 Body Heart Heart 
fe tus  no . wt . (Gm. ) wet (%) dry (%) Liver (%) Kidney (%) Illng (%) 
1 J8. 4 0. 59 0. 07 8. 54 0. 47 0. 97 
2 49. 2 0. 59 0. 07 9. 13 0. 52 1. 26 
'.3 46.2 0 . 76 0. 09 9. 15 0. 59 0. 90 
4 41.7  0. 57 0. 07 10. 04 0. 55 0. 90 
5 45. 5 0. 65 0. 08 9. 99 0. 51 1 . 02 
Mean 44. 2 0. 63 0. 08 9.37 0. 52 1 . 01 
S.  E. 1 .8  0. 03 o . oo 0. 28 0. 01 0. 06 
APPENDIX TABLE 35- Selected Organ Weights of 29 Day Experimental I Rabbit Fetuses Expressed 
as % of Total Body Weight 
Doe ExI#J Body Heart · Heart 
fetus no . wt . (Gm. )  wet (i) dry(%) Ll.ver (%) Kidney (%) Iung(%) 
1 50 . 4  0 . 60 0 . 07 7 . 16 o . 42 1 . 60 
2 52 . 7  0 . 57 0 . 06 7 . 16 0 . 39 1 . 52 
3 36. 7 0 . 59 0 . 07 7 . 33 o .44 1 . 74 
4 52 . 2  0 . 59 0 . 07 7 . 42 0 . 45 1 . 03 
5 44.4 0 . 57 0 . 07 7 . 39 0 . 39 1 . 54 
6 46 .8  0 . 61 0 . 07 7 . 87 o . 41 1 . 33 
7 52 . 2  0 . 54 0 . 07 9 . 40 o . 47 1 . 14 
8 �,5 . 2  0 . 53 0 . 07 8 . 59 o . 4o 1 . 28 
9 52 . 9  0 . 49 0 . 07 8 . 25 o . 41 1 . 05 
Mean 48 . 2 0 . 57 0 . 07 7 . 84 0 . 42 1 . 36 
S.  E. 1 .8  0 . 01 0 . 00 0 . 26 o . oo 0 . 08 
f.," 
APPENDIX TABLE J6- Selected Organ Weights of  29 Day Experimental I Rabbit Fetuses .Expressed 
as % of Total Body Weight 
Doe Ex.I#4 Body P.iea.rt Heart 
fetus no . wt. ( Gi11 . ) wet (%) dry(%) Liver (% ) Kidney (%) lllng(%) 
1 41.4 0 . 57 0 . 07 6 . 86 0 . 38 1 . 70 
2 45 . 6  0 . 55 0 . 06 7 . 25 0 . 39 1 . 34 
3 44. 1  0 . 55 0 . 06 6 . 82 0 . 39 1 . 42 
4 36.3 0 . 63 0 . 07 7.60 0 . 37 1 . 36 
5 56 . 0  0 . 42 0 . 05 7 . 48 o . 42 1 . 16 
6 49 . 6  0 . 52 0 . 06 7 . 38 O . ltO 1 . 50 
Mean 45 . 5  0 . 54 0 . 06 7 . 23 0 . 39 1 . 41 
S .  E. 2 .8 0 . 03 o . oo 0 . 13 o . oo 0 . 07 
t-' ..... 
APPENDIX TABLE 37- Selected Organ Weights of 29 Day Ex:perimental I �bbit Fetuses Expressed 
as % of Total Body Weight 
Doe ExI#=5 &>dy Heart Heart 
fetus no . wt .  (Gm. )  wet (%) dry (%) Liver (%) Kidney(%) Illng (%) 
1 50.8 0 . 45 0.04 8.72 0.37 1 . 57 
2 .5.5.0 0.61 0.06 9.0.5 0 . 39 1.64 
3 50.3 0.52 0 . 05 8.94 0.37 1.32 
4 57.2 0. 53 0.06 9 . 11 0.38 1 . 53 
Mean 53.3 0.53 0.05 8 . 96 0 . 38 1.52 
S. E. 1.7 0.03 o . oo 0.09 o . oo 0.07 
jjp· 
APPENDIX TABLE 38- Selected Organ Weights of 29 Day Ex:perimental I Rabbit Fetuses Expressed 
as % of Total Body We ight 
Doe Ex.I#6 Eody Heart Heart 
fetus no � wt. (Gm. ) wet (%) dry(%) Liver (%) Kidney (%) Illng (%) 
1 53 . 3  0 . 41 0 . 07 5 .8? 0 . 40 1 . 09 
53 .8 0 . 46 0 . 08 6 . 81  0. 32 1 . 05 
Mean 53 . 6  o .44 0 . 08 6 . 34 0 . 36 1 . 07 
S .  E. 0 . 2  0 . 02 o . oo o . 47 0 . 04 0 . 02 
rm� 
APPENDIX TABLE 39- Selected Organ Weights of 29 f}ly Ex:perimental I Rabbit Fetuses Expressed 
as % of Total Body Weight 
Ix> e Ex.I#-1 I3ody Heart Heart 
fetus no. wt. (Gm. ) wet (%) dry (i) Liver (%)  Kidney(%) lung (%) 
1 39.8 0.37 0 . 06 5.40 0. 26 0.84 
2 47 . 0  0 . 38 0 . 06 5. 54 0.33 1. 04 
3 47 . 4  0.36 0 . 05 5.61 0.30 0.87 
4 4J . 7  0.36 0 . 06 5 . 40 0 . 29 0.98 
5 40 . 5  o . 45 0 . 07 5 . 26 0 . 29 0.93 
6 J8 . 2  0 . 40 0.06 4.81 0. 23 0 . 92 
7 56 .8  o . 41 0 . 07 6 . 49 0 . 32 0 . 99 
8 43. 3  0.45 0.07 5 . 49 0 . 31 1 . 05 
9 36.3 0.37 0 . 06 5 . 91 0.35 1 . 18 
Mean 4).7 0.39 0.06 5.55 0. 30 1. 00 
S. E. 2.1 0.01 o . oo 0.15 0 . 01 0.03 
�i' 
APPENDIX TABLE 40- Selected Organ Weights of 29 Day Experimental I .Rabbit Fetuses Expressed 
as % of Total Body Weight 
!be ExI#8 Pody Heart Heart 
fetus no. wt. (Gm. )  wet (%) dry (%) Liver (%) Kidney (%) lung (%) 
1 56. 1  0. 38 0. 06 5 . 62 0. 32 1. 01 
2 56. 6 0. 30 0. 05 6. 12 0. 36 1. 08 
3 47. 1 0. 39 0. 06 4. 97 0. 38 0.81 
4 61 • .5 0. 39 0. 07 5.74 0. 32 0. 90 
5 26 . 6  o.41 0. 06 3 . 66 0. 31 1. 03 
6 35. 7 0 . 36 0. 05 5 . 10 0. 33  1.. 02 
7 57. 6 0. 43 0. 07 5. 24 0. 31 1. 00 
Mean 48. 7 0. 38 0. 06 5. 21 0. 33 0. 98 
s. E. 4. 9 0. 01 o . oo 0. 30 o . oo 0. 03 
APPENDIX TABLE 41- Selected Organ Weights of 29 D�y Ex:perimental I Rabbit Fetuses Expressed 
a3 i of Total Body Weight 
Doe Ex.I#9 Body Heart ·Heart 
fetus no . wt . ( Gm. ) wet (%) dry (%) Liver (%) Kidney (%) lung (%) 
l 55 .8 0. 59 0 . 07 10. 43 0. 50 1. 47 
2 31. 0 0 . 58 0 . 07 7.39 0.44 1. 15 
3 57.6 0 . 57 0. 07 10 . 14 o.42 1.31 
4 49 . 9  0. 52 0. 06 10. 56 0. 44 1.19 
Mean 46. 6 0 . 57 0. 07 9. 63 o.45 1.28 
S . E. 6. 1 0. 01 o . oo 0 .. 75 0. 01 0. 07 
u�f 
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APPENDIX TABLE 42- Selected Organ Weights of 29 Day Experimental II Rabbit Fetuses Expressed 
as % of Total Body Weight 
D:,e EKII#l Pody Heart Heart 
fetus no . wt . (Gm. ) wet (%) dry (%) Liver (%) Kidney (%) lung (%) 
1 46. o  0 . 61 0 . 10 6 . 03 o . 4o 0 . 81 
2 36 . 7 0 . 55 0 . 10 5 . 31 0 . 41 1 . 00 
3 30 . 2  0 . 67 0 . 10 5 . 25 o . 4o 1 . 03 
4 42 . 9  0 . 61 0 . 10 6 . 77 o . 44  1 . 22 
5 53 . 4 0 . 55 0 . 10 6 . 94 o . 4o 1 . 01 
6 50 . 1  0 . 57 0 . 10 7 . 04 o . 44 0 . 96 
7 53 . 6  0 . 57 0 . 10 6 . 71 o . 41 1 . 01 
Mean 44. 7  0 . 59 0 . 10 6 . 29 0 . 41 1 . 01 
S .  E. 3 . 3 0 . 01 0 . 00 0 . 29 o . oo 0 . 04 
APPENDIX TABLE 4J- Selected Organ Weights of 29 Day Experimental II Rabbit Fetuses .Expressed 
as % of Total Body Weight 
Doe "ExII#2 Body Heart Heart 
fetus no. wt. (Gm. )  wet (%) dry (%) Liver (%) Kidney (%) Inng (%) 
1 48 . 6  o.49 0 . 08 4. 76 0. 32 1. 36 
2 49 . 0  0.39 0. 06 6. 07 0. 36 1.22 
J 47.8 0. 52 0. 08 4.21 0. 32 1. 23 
4 40.2 0. 50 0. 08 5. 19 0. 38 0 .90 
5 46.8 0. 58 0 . 09 6. 80 0. 37 1. 16 
6 52. 5 0. 52 0. 09 5.77 0. 35 1. 07 
Mean 47. 5 0. 50 0. 08 5. 47 0. 35 1. 16 
S. E. 1. 7 0. 02 o. oo 0 . 38 o. oo 0 . 06 
APPENDIX TABLE 44- Selected Organ Weights of 29 Day Experimental II Rabbit Fetuses Expressed 
as % of Total Body Weight 
llie ExII#:3 Body Heart Heart 
fetus no . wt . (Gn. ) wet (%) dry (%) Liver (%)  Kidney (%) lung (%) 
1 39 . 4  0 . 30 0 . 04 4 .. 05 0 . 31 1 . 24 
2 Jl . 4  0 . 33 0 . 05 3 . 93 0 . 27 1 . 21 
J 40 . 1  0 . 34 0 . 05 4 . 60 0 . 34 1 .47 
4 36 . 7 0 . 31 0 . 05 5 . 00 0 . 33 1 . 18 
5 39 . 2  0 . 33 0 . 05 5 . 79 0 . 33 1 . 18 
6 37 . 5  0 . 34 0 . 05 5 . 06 0 . 33 1 . 11 
7 44. 2  0 . 31 0 . 04 5 . 18 0 . 33 1 . 16 
8 39.1 0 . 36 0 . 05 5 . 05 0 . 37 1 . 45 
9 34 . 2  0 . 39 0 . 06 l+ . 88 0 . 36 1. 09 
Mean 38 . 0  0 . 33 0 . 05 4 .83 0 . 33 1 . 23 








APPENDIX TABLE 45- Selected Organ Weights of 29 Day :Experimental II Rabbit Fetuses Expressed 
as % of Total Body Weight 
we ExII#4 Body Heart Heart 
fetus no. wt . (Gm. ) wet (%) dry (%) Liver (%) Kidney(%) lung (%) 
1 58. 2 0 . 62 0 . 09 6 . 37 o . 45 1 . 41 
2 53 . 9  o. 49 0. 07 7. 07 0. 42 1. 11 
J 56 . 2  0. 50 0 . 08 6 . 13 0 . 35 1 . 06 
4 57. 0 0. 51 0. 08 6. 02 0.33 1. 04 
5 51 . 5 0 . 61 0 . 10 6. 19 0 . 41 1. 38 
Mean 55. 4 0 . 55 0 . 08 6 . 36 0 . 39 . 1 . 20 
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APPENDIX TABLE 46- Selected Organ Weights of 29 Day Ex:perimental II  Rabbit Fetuses Expressed 
as % of Total Body Weight 
llie ExII#5 Body Heart Heart 
fe tus no . wt. (Gm. ) wet (%) dry (%) Liver (%) Kidney(%) :W.ng (%) 
1 48 .8 0 . 36 0 . 05 5 . 20 0 . 33 1. 14 
2 53 . 2  0 . 38 0 . 06 5 . 68 0 . 28 1 . 03 
J h7 . 4  o . 4o 0 . 05 5 . 40 0 . 36 0 . 99 
4 42 . 1  0 . 36 0 . 05 4 . 67 0 . 31 1 . 14 
5 32 . 0  0 . 36 0 . 05 4 . 01 0 . 29 1 . 02 
6 40 . 7  0 . 40 0 . 06 5 . 61 0 . 31 1 . 03 
7 48 . 0  0 . 39 0 . 06 5 . 87 0 . 26 0 .85 
8 45 . 5 0 . 37 0 . 06 5 . 59 O o 31 1 . 07 
9 40 . 2  0 . 38 0 . 06 5 ., 46 0 . 30 1 . 11 
10 44. 0  0 . 38 0 . 06 5 . 87 0 . 33 1 . 23 
Mean 44 . 2  0 . 38 0 . 06 5 . 34 0 . 31 1 . 06 
S . E.  1 . 9 o . oo o . oo 0 � 18 o . oo 0 . 03 
APPENDIX TABLE 47- Selected Organ Weights of 29 Day Ex:perimental II Rabbit Fetuses Expressed 
as % of Total Body Weight 
lx>e ExII#6 Body Heart · Heart 
fetus no . wt . ( Gm. ) wet (%) dry (%) Liver (%) Kidney (%) lung (%) 
1 44. 9  o .45 0.07 5 . 65 0 . 38 0 .85  
2 57 . 3  0.39 0 . 06 6 . 13 0 . 35 0 . 70 
J 56 . 0  0 . 42 0 . 07 5 . 90 0 . 36 0 . 88 
4 59 . 2  o . 44 0.07 5 . 86 0 . 33 0.79 
5 43 . 7 o . 47 0.08 4. 48 0 . 38 0 . 83 
6 47.2 0 . 44 0 . 07 5 . 00 0. 32 0 . 70 
7 48 . 0  o .43 0 . 07 4 . 82 0. 32 0 . 72 
8 39 . 2  o . 44 0 . 07 4.75 0.25 o.64 
9 45.4 0 . 38 0.06 5 . 06 0 . 37 0 . 57 
Mean 49 . 0  0 .43 0 . 07 5 . 29 . 0 . 34 0 . 74 
s .  E. 2 . 3  o . oo o.oo 0 . 19 0 . 01 0 . 03 
� 
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APPENDIX TABLE 48- Selected Organ Weights of 29 Day Ex:perL�ental II Rabbit Fetuses E,cpressed 
as % of Total Eody Weight 
Doe ExIIi/:7 Body Heart Heart 
fetus no . wt. (Gm. )  wet (%) dry (% ) Liver (%) Kidney(%) Inng (%) 
1 31. 9 0. 38 0 . 05 5. 68 0. 28 1 . 04 
2 31. 4  0. 34 0 . 05 4. 75. 0 . 31 1. 07 
3 33.9 0. 34 0. 05 5 . 00 0 . 31 0. 93 
4 32.8 0. 35 0 . 05 4. 62 0.27 1.24 
5 37. 9 0. 37 0. 05 5 . 25 0. 32 1. 15 
6 32 . 9  0 . 38 0. 05 5 . 05 0 . 34 1. 17 
7 34.4 0. 30 0 . 05 5. 27 0 . 30 1 . 32 
8 J4. 9 0. 36 0 . 05 5. 10 0. 36 0. 95 
Mean JJ .8 0. 35 0 . 05 5. 09 0 . 31 1. 11 
S. E. . 0 . 7 o . oo o . oo 0 . 12 o . oo 0.05 
t-' 
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APPENDIX TABLE 49- Total Fetal Ebdy Weight and Selected Organ Weight (Gm. ) Means from 
Eight Control Doe Litters Showing Grand Mean and Standard Error 
Control No. fetuses Body Heart Heart Ratio 
Doe No . in litter wt. wet dry Liver Kidney lung wet heart/kidney wt. 
Cl 8 42. 7 0 . 2264 0. 0269 3. 2264 0. 1746 0 . 5206 1. 3110 
C2 6 37 . 2  0. 1890 0. 0202 2. 6010 0. 1526 0. 6301 1. 2702 
CJ 9 56. 0  0. 3175 0 . 0396 4. 3775 0. 2825 o. _5864 1. 1376 
C4 7 48.8 0. 2900 o. 0383 4 . 2303 0. 2502 0. 5112 1 . 1710 
cs 6 46 . 5 0. 2284 0. 0307 3. 2939 0. 2016 0. 6204 1 . 1447 
C6 9 33. 4  0. 1782 0. 0202 2. 4365  0. 1308 0. 5389  1. 3834 
C? 6 33. 8 0. 1264 o .  0183  1. 6958 0. 1205 0. 4850 1. 0540 
C8 6 42. 2 0. 1739 0. 0282 2 . 1239 0. 1555 0. 4806 1. 1568 
Grand 
Mean 42 . 6  0. 2162 0 . 0278 2. 9981 0. 1835 0 . 5466 1 . 2035 




APPENDIX TABLE 50- Total Fetal Body Weight and Selected Organ Weight (Gm. ) Means from Nine 
Experimental I Doe Litters Showing Grand Mean and Standard Error 
Ex I No . fetuses Body Heart Heart Ratio 
Doe No . in litter wt . wet dry- Liver Kidney Il.mg wet heart/kidney wt . 
ExI 1 2 57. 7 0. 3384 0. 0412 5. 0235 0. 2667 0.9615 1. 2743 
ExI 2 5 44. 2 0. 2828 0. 0361 4. 1473 0. 2360 0. 4519 1. 1976 
ExI 3 9 48. 2 0. 2738 0. 0349 3. 7873 0. 2047 o.6491 1 . 3454 
ExI 4 6 45. 5  0. 2437 0 . 0295 3. 2968 0. 1809 0.6393 1. 3850 
ExI 5 4 53. 3  0. 2848 0. 0326 4. 7814 0. 2027 0.8118 1. 3984 
ExI 6 2 53. 6  0. 2348 0. 0415 3. 3973 0. 1978 0. 5742 1. 2073 
ExI 7 9 43. 7 0. 1785 0. 0290 2.4414 0. 1331 o. 4278 1. 3454 
ExI  8 7 48. 7 0 . 1867 0. 0328 2 . 6164 0.1659 0.4771 1. 1443 
ExI 9 4 48.6 0 . 2764 0. 0358 4.8085  0. 2225 0.6343 1. 2480 
Grand 
Mean 49. 3 0. 2555 0. 0348 3 . 8111 0. 2011 0.6252 1 . 2828 









APPENDIX TABLE 51- Total Fetal Body Weight and Selected Organ Weight (Gm. ) Means from Seven 
Experimental II Doe Litters Showing Grand Mean and Standard Error 
ExII No. fetuses Body Heart Heart Ratio 
Doe No . in litter wt. wet dry Liver Kidney Illng wet heart/ kidney wt. 
ExII 1 7 44. ? 0. 2641 0. Ol�66 2.8653 0. 1877 o.4499 1. 4234 
Ex:II 2 6 47. 5 0. 2398 0. 0403 2 . 6029 0 . 1696 0 . 5553 1.4176 
ExII J 9 38 . 0  0. 1279 0. 0197 1. 8470 0. 1273 o.4716 1. 0135 
ExII 4 5 55. 4  O. 30 58 0. 0498 3. 5203 0. 2198 o. 6668 1. 3988 
ExII 5 10 44. 2  0. 1696 0. 0273 2. 3815  0. 1383  0. 4700 1 .2336 
Ex:II 6 9 l.j,9. 0 0. 2121 0. 0366 2. 6259 0. 1706 0. 3678 1. 2739 
ExII 7 8 33.8 0 . 1206 0. 0190 1. 7213 0 . 1068 0. 3766 1. 1382 
Grand 
Mean 44. 7 0. 2057 0 . 0341 . 2. 5091 0. 1600 o . 4797 1. 2712 








APPENDIX TABLE 52- Total Fetal Body Weight and Selected Organ Weight (Gm. ) Means Expressed as 
% of Total Body Weight from Eight Control Doe Litters Showing 
Grand Mean and Standard Error 
Control No . fetuses Body Heart Heart 
Doe No . in litter wt. wet dry Liver Kidney I.llng 
Cl 8 42 . 7  0 . 53 0 . 06 7 . 52 0 . 40 1 . 21 
C2 6 37 . 2  0 . 51 0. 05 6 . 98 0 . 41 1 . 69 
CJ 9 56 . 0  0 . 56 0 . 06 7 . 79 o . 49 1 . 04 
C4 7 48 .8  0 . 59 0 . 07 8 .  9-} 0 . 50 1 . 04 
c5 6 46 . 5  o . 48 0 . 05 7 . 01 o . 42 1 . 32 
C6 9 33 . 4 0 . 53 0 .. 05 7 . 24 0 . 38 1 . 60 
C? 6 33 . 8  0 . 37 0 . 05 4 . 98 0 . 35 1 . 43 
C8 6 42 . 2  0 . 42 0 . 06 4 . 97 c . 36 1 . 14 
Grand 
Moan 42 . 6  0 . 50 0 . 06 6 .88 o . 41 1 . 31 
S . E.  2 .8 0 . 02 o . oo 0 . 45 0 . 02 0 . 09 
mt�· 
APPENDIX TABLE 53- Total Fetal Body Weight and Selected Organ Weight (Gm. ) Means Expressed as 
% of Total Eody Weight from Nine Experimental I Doe Litters Showing 
Grand Mean and Standard Error 
ExI No. fetuses Body Heart Heart 
Doe No . in litter wt. wet dry Liver Kidney Iung 
ExI 1 2 57 . 7  0 . 58 0 . 06 8 . 71 o . 46 1.66 
ExI 2 5 44. 2  0 . 63 0 . 08 9 . 37 0 . 52 1 . 01 
ExI 3 9 48 . 2  0 . 57 0 . 07 7 . 84 o.42 1 . 36 
ExI 4 6 45 . 5  0 . 54 0 . 06 7 . 23 0 . 39 1 . 41 
ExI 5 4 53 . 3  0 . 53 0 . 05 8 . 96 0 . 38 1 . 52 
Ex I 6 2 53 . 6  o . 44 0 . 08 6 . 34 0 . 36 1.07 
ExI 7 9 43 . 7  0 . 39 0.06 5 . 55 0 . 30 1 . 00 
ExI 8 7 48 . 7  0 . 38 0 . 06 5 . 21 0 . 33 0.98 
ExI  9 4 48 . 6  0 . 57 0 . 07 9 . 63 0 . 45 1 . 28. 
Grand 
Mean 49 . J 0 . 51 0 . 07 7 . 65 o . 4o 1 . 25 







APPENDIX TABLE 54- Total Fetal P.ody Weight and Selected Organ Weight (Gm. ) Means Expressed as 
1.i of Total Body Weight irom Seven Experimental II Doe L.-t tters Showing 
Grand Mean  and Standard Error 
ExII No . fetuses Body Heart Heart 
Doe No . in litter wt . wet dry Liver Kidney lung 
ExII 1 7 44. 7  0 . 59 0 . 10 6 . 29 o . 41 1 . 01 
ExII 2 6 47 . 5 0 . 50 0 . 08 5 . 47 0 . 35 1 . 16 
&cII J 9 38 . 0  0 . 33 0 . 05 4 . 83 0 . 3:3 1 . 23 
Ex:II 4 5 55 . 4  0 . 55 0 . 08 6 . 36 0 . 39 1. 20 
&:II 5 10 44. 2  0 . 38 0 . 06 5 . 34 0 . 31 1 . 06 
ExII 6 9 49 . 0  0 . 43 0 . 07 _5 . 29 0 . 34 0 . 74 
ExII 7 8 33 .8  0 . 35 0 . 05 5 . 09 0 . 31 1 . 11 
Grand 
Mean 44. 7  0 . 45 0 . 07 5. 52 0 . 35 1 . 07 
S .  E. 2 . 7 0 . 04 o . oo 0 . 22 0 . 01 0 . 06 
